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Abstract 
Ninety percent of breast cancer-related mortalities result from metastasis. We have previously 
demonstrated that stem-like ALDHhiCD44+ breast cancer cells are critical for metastasis, and 
preferentially target the lung and bone marrow (BM). We hypothesize organ tropism occurs 
through promotion of the ALDHhiCD44+ phenotype. Using a 2D ex vivo model, lung and BM 
conditioned media (CM) were utilized to assess their influence on stem-like phenotype and 
behavior. Exposure of human breast cancer cells to lung-CM significantly decreased the 
proportion of cells with a stem-like ALDHhiCD44+ phenotype, decreased expression of cancer 
stem cell (CSC)-related genes, and increased gene expression related to migration (p<0.05). 
Lung-CM also induced a viable non-adherent subpopulation that expressed significantly 
decreased CD44 expression and was unable to form mammospheres (p<0.05). Analysis of 
lung-CM revealed presence of proteins related to migration, adhesion, and stemness. Taken 
together, the lung microenvironment may promote metastasis of breast cancer cells in a CSC-
independent manner. 
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1 INTRODUCTION 
Cancer is devastating. It is the source of physical, emotional, and mental stress that not 
only affects the immediate individual involved, but extends further to family and friends. 
In 2017 alone, it is estimated that 206,200 Canadians will be diagnosed with cancer1. These 
figures have increased by nearly 10,000 new diagnoses within the past two years2. 
Unfortunately, these figures are expected to rise by an additional 20% by 2020 largely due 
an aging and growing population3. Greater emphasis on cancer prevention, adopting a 
healthy lifestyle, and earlier detection is necessary to counter such undesirable outcomes3.  
Breast cancer is the most common malignancy in women worldwide4. Despite its high 
prevalence, patient prognosis is strong with 5-year survival rates nearing 99% when 
localized to the breast5. Once the cancer leaves the confines of the breast, the chances of 
surviving this drastically decrease5. In fact, the dissemination of cancer from the primary 
affected region to distant organs accounts for 90% of all cancer related deaths6. Recently, 
it has been proposed that a rare population of tumour cells, commonly referred to as cancer 
stem cells, may be mediating metastasis and secondary tumour formation7. Therefore, 
mortality related to breast cancer rarely occurs as a result of the primary tumour, but rather 
the cascading effect of multiple organs becoming compromised, including the lung and 
bone 8-10.  
The focus of this thesis is to investigate the importance of the native lung and bone marrow 
microenvironments in promoting rare, highly malignant cells to target these organs as 
likely sites of metastasis. Understanding the role of the microenvironment is crucial to gain 
a comprehensive understanding of cancer metastasis. 
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2 LITERATURE REVIEW 
 Cancer 
The term “cancer” encompasses a subset of diseases that are characterized by atypical cell 
growth and proliferative patterns. As these aberrant cells develop, they acquire genetic 
disruptions that enable sustained proliferative signaling and evasion of growth 
suppressors11. Most often, the onset of this disease begins once genes involved in cell cycle 
regulation become mutated and dysfunctional. These genes are most often classified either 
as oncogenes or tumour suppressor genes. Once mutated, oncogenes become activated, 
giving cells the ability to induce uncontrolled cell growth12. In contrast, mutations in 
tumour suppressor genes may render normal cells incapable of DNA repair required to 
regulate cell growth13. It is likely that oncogene activation and tumour suppressor gene 
inactivation occur simultaneously as cancer progresses, ultimately resulting in tumour 
formation14.  
Tumours can be characterized by their benign or malignant nature, with the latter capable 
of invasive traits that represent the hallmarks of cancer. A growth that is neither invasive 
to surrounding or distant regions, such as a common wart, is considered benign and does 
not pose a significant health risk11. In rare cases, benign tumours may impinge on blood 
vessels or nerves that supply organ systems. These instances are considered higher risk and 
require resection, however they are not considered malignant tumours15. Malignant 
tumours tend to be life-threatening due to the capacity to leave the primary site and invade 
into surrounding tissues or distant secondary sites of the body via access to systemic 
circulation15. These tumours are referred to as malignant cancers and require early 
detection and subsequent treatment to provide the best prognosis for patients. In later stages 
of tumour progression, if the tumour has spread to distant sites, both primary and adjuvant 
treatments (e.g. tumour resection, radiation, hormonal therapy, or chemotherapy) become 
far less efficient at easing tumour burden16. Together, inefficiencies in treatment strategies 
and efficacy leave both patients and the healthcare system in distress.  
In 2017 alone, 1 in 4 Canadians will no longer be responsive to traditional cancer treatments 
and will eventually succumb to the disease1. Further, the Canadian Cancer Society 
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estimates that 1 in 2 Canadians will develop cancer within their lifetime, a value that is 
increased from a 1 in 2.5 frequency just two years ago1,2.  Similarly, the overall 5-year 
survival rates in cancer patients have also decreased from 63% in 2015, to 60% in 20171,2. 
Despite advances in targeted treatment and enhanced screening techniques, cancer is 
proving to be relentless. If these patterns persist, cancer-associated deaths will account for 
30% of Canadian premature deaths in 2017, 1. Premature deaths are measured by potential 
years of life lost (PYLL) and account for deaths occurring at younger ages, a vital statistic 
when assessing economic health for any given country. Between 2010 and 2012, cancer 
represented the largest PYLL among Canadians, with 1.5 million years lost due to cancer1. 
Due to a loss in productivity associated with high PYLL values, not only is the growing 
Canadian economy impacted, but these patients also pose a significant financial burden on 
the healthcare system. In 2008, the Public Health Agency of Canada estimated that $3.8 
billion was devoted to direct healthcare costs for cancer patients (hospitalization, 
treatments, etc.), while an additional $586 million was lost to indirect costs associated with 
decreased economic productivity17. Considering that cancer diagnoses have increased in 
recent years, the economic impact of cancer is expected to increase steadily with time. 
 Breast Cancer 
The breasts are two prominences situated on the ventral torso of primates, morphologically 
identical in both male and female offspring. Once females enter puberty, secretion of sex 
and growth hormones (namely estrogen) promote mammary development.  Subcutaneous 
adipose tissue within the breast supports a network of ductal and lobular tissue, that 
together, comprise the feeding mammary gland. The lobular epithelium of the breast serves 
a lactiferous function, producing and secreting milk down the ductal epithelium for 
expulsion out the nipple by contracting myoepithelial cells 18. Due to hormonal cycling 
involved in mammary development and throughout child-bearing years, the lobular and 
ductal cells are most susceptible to tumour formation, and cancers that arise are termed 
lobular or ductal carcinomas respectively16. So long as the tumour is confined to primary 
breast tissue, the 5-year survival rate is an exceptional 98.6% among females5. 
Unfortunately, this prognosis significantly decreases to ~25% once the cancer 
metastasizes, spreading from the breast tissue and reaching secondary sites5. The most 
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aggressive cases of breast cancer involve secondary tumour formation at distant organs, 
resulting in significantly reduced organ function.  
 Histopathology and Molecular Subtypes 
Recent findings regarding tumour heterogeneity suggest that each tumour is distinct and 
unique from patient-to-patient. This further extends into distinctions between multiple 
tumours identified within a single individual. Upon histopathological analyses of biopsied 
tumour samples from the breast, inter-tumour heterogeneity is evident19. Histopathology 
provides a rudimentary understanding of the cell subpopulations involved in tumour 
development, their morphology, and predicting aberrant growth patterns. The main 
purpose of this technique is to distinguish whether the breast tumour is originating from 
ductal or lobular tissue architecture20. At the time of detection, ductal or lobular carcinomas 
in situ (DCIS or LCIS respectively) are non-invasive as they remain confined to epithelial-
lined compartments within the mammary tissue20. Surgical resection and localized therapy 
strategies such as radiation are highly effective and demonstrate strong patient prognosis 
with a 99% survival outlook over five years21. Unfortunately, more than half of breast 
cancer incidences are invasive ductal or lobular carcinomas (IDC or ILC) upon initial 
diagnosis22. Tumours that have spread from epithelial-lined compartments of the mammary 
tissue into the stroma are classified as invasive carcinomas through histopathological 
analyses20. The associated treatment strategies for patients with IDC or ILC are less 
effective and become limited as the tumour spreads from the primary tissue. A lack of 
targeted therapies for invasive carcinomas is reflected in the 5-year survival rates dropping 
to near 25% once the tumour has acquired invasive potential21.  
In addition to histopathological distinction between breast cancer tumours, molecular 
classification of breast cancer cells has provided further insight regarding the cells 
propagating tumour growth and development. Among the invasive incidences of breast 
cancer, the four main molecular subtypes of interest are: Luminal A, Luminal B, HER2-
enriched and basal-like (or triple-negative; TN) breast cancer23. The basis of this 
classification system is dependent on cell surface expression of hormonal receptors and 
intrinsic proliferation status of the cell. Luminal A breast cancer cells have a distinct 
phenotype expressing receptors for the hormones estrogen and progesterone (ER+ and 
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PR+), and lacking human epidermal growth factor receptor 2 (HER2-)24. Breast cancer 
cells with a high proliferative (Ki67) index and/or expressing HER2, in addition to both 
ER+/PR+, are classified as the Luminal B subtype. Both luminal A and B breast cancers 
have been associated with positive survival outcomes24,25. Because both Luminal A and B 
subtypes are ER+, hormone therapy is highly effective to treat patients, particularly in the 
adjuvant setting19. Despite their similarities, Luminal B breast cancer cells are genetically 
altered from the Luminal A subtype, resulting in poorer prognosis than those affected by 
Luminal A breast cancer26. Further, the HER2+ breast cancer subtype lacks expression of 
both ER and PR, rendering these cells unresponsive to targeted hormone therapy24. 
Together with increased proliferation within this subtype, HER2+ breast cancer cells tend 
to metastasize and spread more readily to surrounding tissues, resulting in poorer patient 
prognosis relative to luminal breast cancers23. Inhibition of HER2+ ligand-receptor 
interactions using HER2-targeting agents such as trastuzumab and lapatinib has improved 
overall patient survival and time-to-disease progression, however many patients will 
acquire resistance to therapy over time27.  
Perhaps the most difficult breast cancer subtype to treat is the TN breast cancer subtype 
which lacks the cell surface receptors found on the aforementioned breast cancer subtypes 
(ER-/PR-/and HER2-)24. Often the most aggressive subtype of breast cancer, TN breast 
cancer patients are highly prone to metastases which results in the poorest prognosis28. 
Despite some TN breast cancers being initially responsive to traditional chemotherapy, a 
hallmark of TN breast cancer is their high likelihood of distant recurrences within 3-years 
of initial diagnosis29. As endocrine treatment strategies targeting ER/PR/ or HER2 are 
ineffective on the TN subtype, central pathways involved in proliferation, growth and 
migration are being actively investigated as potential targets30.  
Although our understanding of molecular breast cancer subtypes has provided avenues for 
clinical intervention, it is important to consider intra-tumour heterogeneity as a factor for 
disease recurrence post-treatment. Cells from different regions of a solid breast tumour 
have shown varying levels ER, PR, and HER2 cell surface expression which is consistent 
with intra-tumour heterogeneity31. Thus, when investigating a heterogenous tumour, it is 
important to consider that each population of cells has a distinct composition that may 
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modulate tumour progression through intrinsic factors such as migration and/or invasion19. 
 Epithelial-to-Mesenchymal Transition 
Given the anatomical composition and functional nature of mammary tissues, primary 
tumours developing in the breast are epithelial-derived and termed carcinomas32. 
Understanding how healthy epithelial cells function to maintain homeostasis is necessary 
to predict changes in epithelial function in a diseased state. The epithelial cell utilizes 
networks of cell-cell and cell-extracellular matrix (ECM) interactions to provide apical-
basal cell polarity. Desmosomes, adherens junctions and gap junctions are protein 
complexes that maintain physical association between adjacent epithelial cells (cell-cell), 
while cell-ECM interactions are necessitated by integrins and cell adhesion molecules 
(CAMs)33,34. In a dynamic and invasive tumour microenvironment, extracellular cues 
reduce characteristic epithelial cell-cell and cell-ECM interactions, and can induce a 
mesenchymal cell phenotype35. The epithelial-to-mesenchymal transition (EMT) and its 
reverse process, mesenchymal-to-epithelial transition (MET) describe this transformation 
from one phenotype to another7. Once in the mesenchymal state, these cells lack apical-
basal polarity and possess increased migratory and invasive potential36,37. The role of EMT 
and MET were first documented in embryogenesis, but the importance of these processes 
further translates into cancer progression, and subsequently metastasis7,38. Cancer 
progression requires cells of the primary tumour to disassociate and invade into the 
surrounding stroma. This process of invasion is mediated in part by the loss of cell-cell 
adhesions, which enhances cellular motility, while deterioration of cell-ECM interactions 
allows catabolic cell secretions (e.g. matrix metalloproteinases; MMPs) to penetrate the 
basement membrane34,37. As tumourigenic cells penetrate the porous basement membrane 
and extend into the surrounding stroma, early stage carcinomas become invasive 
malignancies7. In order to support tumourigenic growth, invading cells secrete angiogenic 
factors (such as vascular endothelial growth factor [VEGF] and transforming growth factor 
beta [TGF-β]) to support vascular growth necessary for nutrient delivery towards the 
tumour34,37. Although recent studies document maintained tumour progression in the 
absence of vascular recruitment (hypoxic conditions), vascular growth is necessary for 
tumourigenic cells to invade systemic circulation and metastasize to distant sites34,37,39. 
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 Metastasis 
The spread of cancer from a primary tumour to a distant secondary site is referred to as 
metastasis, or metastatic disease. Although treatment strategies targeting the primary 
tumour are highly efficient, nearly 30% of women diagnosed with early-stage breast cancer 
will ultimately develop metastatic lesions40-42. For tumourigenic cells to metastasize, they 
must leave the primary site and enter systemic circulation by directly invading the 
surrounding vasculature, or indirectly through the lymphatic system43. As previously 
mentioned, the invasive behaviour of cancer cells induced by EMT and other mechanisms 
allows cancer cells to invade the surrounding stroma. Together with enhanced vascular 
recruitment (angiogenesis and vasculogenesis) surrounding the primary tumour site, cancer 
cells further develop means to enter into the vasculature/lymphatics and leave the primary 
site43-45.  
Millions of cells are capable of dissociating from the primary tumour and entering the 
vasculature every day. However, the relative incidence of metastatic tumour development 
is rare, suggesting that the metastatic process has inefficiencies42. As tumour cells 
intravasate into the circulation, experimental studies have shown that >80% of these cells 
can survive the shear and compressive stress associated with the circulatory phase of 
metastasis41,42,46.  The majority of these circulating tumour cells (CTCs) arrest in the first 
capillary bed they encounter, while others remain selective for specific organ 
microenvironments such as the bone, lung, and brain47-49. Only after successful 
extravasation, whereby the CTCs exit the circulation and invade the distant organ, can 
secondary tumour formation become possible43. Despite the large number of cells that 
survive the circulatory phase of metastasis and successfully extravasate at the secondary 
site, the inefficiencies associated with metastasis are highlighted when assessing tumour-
initiating potential at the distant tissue. Experimental studies have shown that only ~2% of 
cancer cells that successfully reach the secondary tissue microenvironment have the 
capacity to initiate a new tumour, and <0.1% of cells can persist into the successful 
formation of macrometastases42. These inefficiencies suggest that aspects of the metastatic 
microenvironment and/or characteristics of cancer cells can contribute to the success or 
failure of metastasis. 
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 Organ Tropism of Metastasis 
In the event of metastasis, patterns of cancer dissemination to secondary sites are not 
random, but rather coordinated50. Many cancers have shown preferential metastatic 
capacity towards particular organs, a process referred to as organ tropism. Among the 
various cancer subtypes, the patterns of organ tropism are variable and dependent on the 
cancers’ origin. Some cancers predominantly metastasize to a specific organ (e.g. prostate 
cancer metastasizing to the bone), while other cancers follow a sequential pattern of 
metastasis (e.g. colorectal cancer often forms secondary metastases in the bone  lung  
brain)51. As each organ differs in anatomical position, blood/nutrient supply, and organ 
microenvironment composition, invading tumour cells face different demands based on the 
target organ. Clinically, breast cancer metastasis has demonstrated preferential metastasis 
to the lung, bone, liver, brain and lymph nodes52.  
Two competing theories that attempt to elucidate mechanisms involved in organ-specific 
metastasis are Stephen Paget’s “seed and soil” hypothesis, and Ewing’s mechanical arrest 
theory. Initially Paget, a British surgeon, theorized that cancer cells (the “seed”) require an 
organ microenvironment (the “soil”) that can adequately support the growth of a metastatic 
tumour53. Thus, for a metastatic tumour to successfully grow, there is a requirement for 
favorable factors within the organ microenvironment capable of supporting tumour 
formation. Strengthening Paget’s theory, recent findings in breast cancer research 
demonstrate the luminal breast cancer subtype to preferentially metastasize to the bone, 
while the HER2+ subtype often targets the liver54-56.  Half a century later, James Ewing 
proposed a novel mechanism dependent on physical characteristics of blood flow through 
the circulatory system that dictate eventual sites of mechanical arrest. He proposed that 
organs with the largest blood supply would be most prone to acquiring blood-borne 
metastatic cells, leading to tumour cell arrest at the first capillary bed they encounter and 
initiating secondary tumour formation57. In theory, Ewing’s mechanism holds strength, 
however fails to fully explain clinical patterns of organ-specific metastasis. Despite 
receiving a similar 10%-20% of blood volume, the liver, kidney and brain tissue each show 
different patterns of susceptibility to metastasis development, highlighting the oversight in 
Ewing’s theory58.  
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When considering a biologically relevant theory for organ tropism, the likely mechanism 
is a combination of both Paget’s and Ewing’s hypotheses. A complex system that delivers 
metastatic cells to different organ tissues based on relative blood supply, and then initiation 
and maintenance of said tumour would be mediated by favourable interactions with the 
soluble and insoluble factors provided by the organ.59,60. 
 The “Seeds”: Stem-Like Breast Cancer Cells 
Research conducted by Massagué and colleagues uncovered an association between the 
molecular characteristics of breast cancer cell (the “seed”) and the preferential tissue to 
which the breast cancer cells metastasize52. Using in vitro and in vivo studies with the triple-
negative MDA-MB-231 human breast cancer cell line, they demonstrated that specific 
gene expression signatures can dictate a breast cancer cell’s preference to metastasize to 
either the lung, the bone, or the brain47-49. However, this work did not take into 
consideration the heterogeneous nature of primary metastatic breast cancer tumours. 
Subsequent limiting dilution analyses in vivo confirmed this notion by demonstrating that 
isolation and injection of low numbers of primary breast cancer cells into healthy immune 
deficient mice resulted in only a small fraction of cells harnessing the ability to initiate and 
produce a primary tumour61,62. These studies supported the idea that only a subset of cells 
within a primary tumor have tumour-initiating capacity, suggesting that this rare 
subpopulation may contain stem-like traits, often referred to as cancer stem cells (CSCs). 
The concept of a CSC subpopulation within tumours first originated in hematologic 
cancers, gaining credibility with evidence that only 1 to 4% of myeloma and leukemia 
cancer cells demonstrated enhanced proliferative and colony formation potential63-65. 
Although the cellular origins of cancer stem cells in some solid tumours remain 
controversial, recent studies conducted by Blanpain et al have successfully demonstrated 
that tumour populations in intestinal, prostate, and breast cancer can be traced back to a 
stem/progenitor origin, reinforcing the validity of CSC model66. 
 Characterization of CSCs 
Current methods of CSC characterization have been adapted from the pioneering field of 
hematopoietic stem cells (HSCs). Discovered first by James Till and Ernest McCulloch 
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during their investigation of hematopoietic system regeneration in vivo, a true HSC must 
fulfill two requirements: the ability to self-renew and to maintain a multipotent state67. Self-
renewal refers to the cells’ ability to produce a sister HSC without losing multipotent 
potential, while multipotency is the ability of a progenitor cell to differentiate into any 
functional cell within a given lineage67,68.  Originating from these well-characterized HSC 
attributes, CSCs must be able to generate a heterogeneous tumour population 
(differentiation) while concomitantly maintaining their own population (self-renewal)68. 
Numerous studies have validated these stem cell characteristics to be true among a CSC 
subpopulation, and in addition, have demonstrated that CSCs also possess enhanced drug 
resistance, anchorage-independence, and increased migration relative to non-
CSCs52,61,62,69,70. CSCs have also been associated with aggressive metastasis, and in many 
instances, found to express molecular markers of EMT7. Considering the inefficiencies 
previously mentioned regarding the metastatic process, it is reasonable to postulate that a 
rare CSC subpopulation of primary breast cancer cells may also be able to establish and 
drive distant secondary tumour development. 
In light of their stem-like properties, CSCs can be isolated from a whole cell population 
using similar molecular screening techniques used with HSCs. In breast cancer, CSCs from 
patient tumours and various breast cancer cell lines have successfully been enriched for 
based on high aldehyde dehydrogenase (ALDH) enzymatic activity and the co-expression 
of the cluster of differentiation 44 (CD44) cell surface marker61,62,71.  
2.6.1.1 ALDH 
The ALDH family is made up of 19 evolutionarily conserved isoenzymes that are localized 
intracellularly in the cytoplasm, mitochondria, and nucleus72. The main function of ALDH 
is to catalyze the oxidation of aldehydes into carboxylic acids, along with other functions 
such as ester hydrolysis and scavenging for hydroxyl radicals72. Of particular interest are 
the isoenzymes (ALDH1A1, ALDH1A2, ALDH1A3, and ALDH8A1) involved in the 
conversion of vitamin D to retinoic acid (RA), as they have recently been implicated in 
cancer cell “stemness”73.  The lipophilic RA molecule is capable of passive diffusion in a 
paracrine or endocrine manner, resulting in induced transcription of biological genes 
related to proliferation, differentiation, cell cycle arrest, and apoptotic pathways74. Notably, 
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the human cytosolic ALDH1A subfamily (ALDH1A1 and ALDH1A3) are highly 
expressed in early progenitor cells and have been documented to overlap with side 
population cells capable of excluding Hoechst 33342 stain, another modality for 
identifying stem-like cells61. Intrinsically high ALDH (ALDHhi) activity and Hoechst 
33342 excluding stem-like side populations demonstrate increased expression of ABC 
transporters, a feature thought to provide CSCs with chemo-resistance75. This protective 
mechanism renders CSCs particularly resistant to conventional cancer therapies, permitting 
relapse over complete remission, and prolonging tumour longevity7,76. Much of the 
research concerning ALDH activity in cancer utilizes the metabolism of ALDEFLUOR™ 
substrate to isolate a subpopulation of tumourigenic cells with stem-like characteristics via 
flow cytometry72. It was initially predicted that ALDH1A1 was responsible for the majority 
of ALDEFLUOR™ metabolism, however recent evidence suggests ALDH1A3 is also 
involved72,74. Considering the metabolism of ALDEFLUOR™ is non-specific, it is likely 
that the ALDH activity detected in a cancer is due to the combined activity of two or more 
ALDH isoforms72.  
Analyses of intracellular ALDH activity in liver, lung, esophageal, and breast cancer cells 
has been a useful tool to estimate how these tumourigenic cells may behave in vivo73. In 
breast cancer, cells with elevated ALDH activity have demonstrated increased migratory 
capacity and the ability to form mammospheres in vitro70,77. The importance of ALDH 
activity in vivo was emphasized by Ginestier et al. after transplantation of 50,000 ALDHlo 
human breast cancer cells into the mammary fat pad of immunocompromised mice was 
insufficient for tumour formation, but transplantation as few as 500 ALDHhi cells resulted 
in tumour formation within 40 days61,78. Both ALDH1A1 and ALDH1A3 have been 
implicated in driving tumourigenesis after breast cancer cell transplantation in xenograft 
models79,80. Moreover, Marcato et al demonstrated ALDH1A3 overexpression in human 
breast cancer cells is case specific, as ALDH1A3 overexpression was tumour-promoting 
in MDA-MB-435 and MDA-MB-231 cell lines, while tumour-suppressive in MDA-MB-
468 cells79. Clinically, Marselos et al identified ALDHhi activity to have a strong 
correlation with metastatic lesions among patients with colon cancer, relative to healthy 
adjacent tissues81. More recently, a study of 87 female patients diagnosed with metastatic 
breast cancer found the incidence of ALDH1 expression significantly increased in the 
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metastatic site (43.7%) compared to the primary tumour (28.7%), suggesting the 
importance of ALDH1 in metastatic disease and secondary tumour formation82. With 
accumulating evidence supporting the tumorigenic role of ALDH in patients with 
metastatic breast cancer, a meta-analysis assessing 921 patients for elevated ALDH1A1 
expression in breast cancer tumours concluded that ALDH1A1+ can be used as a biomarker 
for the prediction of tumour progression and poor patient outcome83.  
2.6.1.2 CD44 
Membrane-spanning CD44 is a glycosylated cell surface receptor that has well-defined 
roles in cell-cell and cytoskeletal cell-ECM interactions (via Rho GTPase signaling), 
promotion of cell survival and invasion (via PI3/Akt and MAPK-Ras pathways). 
Importantly, CD44 has a strong association with cell migration through interactions with 
matrix metalloproteases (MMPs) and other matrix remodeling enzymes which together 
coordinate cellular locomotion62,84. The principal ligand for CD44 is hyaluronic acid (HA), 
a major component of extracellular matrices, which has also been reported to maintain long 
term self-renewal85. Functional CD44 protein is encoded by a single gene with 20 exons, 
where exons 1-5 and 16-20 comprise the standard isoform (CD44s), while exons 6-15 are 
alternatively spliced to produce CD44 variants (CD44v)86. Although CD44s has been 
implicated repeatedly in a variety of cancers, recent investigations have begun to examine 
specific splice variants and their association in cancer progression87. CD44v4 in human 
breast cancer cells was found to preferentially interact with E-selectin expressed human 
umbilical vein endothelial cells (HUVECs) and promoted trans-migration88. Moreover, a 
clinicopathologic study investigating the role of CD44v6 in 85 untreated primary breast 
cancer patients reported that a decrease in CD44v6 mRNA correlated with poor survival89. 
Due to conflicting data suggesting upregulation and/or downregulation of certain CD44v 
isoforms implicated in cancer development, the CD44s isoform is most consistently used 
for CD44 assessment90. Nevertheless, CD44 remains an important marker for identification 
of tumourigenic cancer cell populations, both in vitro and in vivo. Research conducted by 
Al-Hajj et al successfully identified a CD44+/CD24- subpopulation of breast cancer cells 
with heightened CSCs characteristics. In vivo studies demonstrate that as few as 100 
CD44+/CD24- cells were capable of forming tumours in mice, while the CD44-/CD24+ 
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subpopulation was unable to form tumours, even after injection of 500,000 cells62. These 
findings suggest CD44 expression has an important role in tumour development. 
 Stem-Like Cancer Cells and Metastasis 
Metastasis has been correlated with poor overall survival and mortality in several types of 
cancers, a major obstacle in cancer treatment. The involvement of CSCs in metastatic 
disease has received particular attention because they have been implicated in the initiation 
of the metastatic cascade through EMT processes91. Interestingly, both ALDH and/or 
CD44 have been used as markers for the identification of metastasis-prone cancer cell 
subpopulations. Previous investigation conducted in the Allan lab by Croker et al found 
breast cancer cells expressing the stem-like ALDHhiCD44+ phenotype demonstrated 
enhanced metastatic behavior in vitro, as their ability to migrate and invade was 
significantly increased relative to the non-CSC ALDHlowCD44- subpopulation70. 
Moreover, these stem-like breast cancer cells exhibited increased ability to form 
anchorage-independent colonies in vitro when compared to non-CSCs, suggesting these 
cells could potentially colonize in a distant organ microenvironment after detachment and 
dissemination70. Subsequent in vivo analyses confirmed the metastatic potential of stem-
like breast cancer cells after orthotopic injection into the mammary fat pad of NOD/SCID-
IL2Rγ mice led to increased spontaneous metastases to the liver, spleen, and most notably 
the lung70. Not only did stem-like cells preferentially metastasize to these organs relative 
to their non-CSC counterpart, the mean tumour volume and metastatic burden to the lung 
was significantly increased in mice injected with the stem-like breast cancer cell 
subpopulation70. Surprisingly, investigation of ALDH1A1 and ALDH1A3 isoenzymes 
demonstrated differential roles related to their involvement in metastasis92. Using a 
knockdown model, human breast cancer cells devoid of ALDH1A1 demonstrated a 
significant reduction in their ability to migrate, and were less adherent in vitro92. In 
contrast, knockdown of ALDH1A3 resulted in increased cell migration and adhesion in 
vitro92. Knockdown of either ALDH1A1 or ALDH1A3 significantly decreased the number 
of tumoursphere colonies formed in vitro92. Further, in a chick chorioallantoic membrane 
(CAM) assay, ALDH1A1 knockdown resulted in reduced ability to of breast cancer cells 
to extravasate from the vasculature, as well as reduced number of micrometastatic tumours 
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with either knockout of ALDH1A1 or ALDH1A392. Collectively, ALDH activity among 
CSC subpopulations has been demonstrated to be a critical factor in cancer dissemination 
through coordinated activity of ALDH1 isoenzymes. 
The concerns revolving around CSCs and metastasis extend past their ability to disseminate 
and colonize distant organs. Tumour cells expressing stem-like characteristics present a 
significant barrier between effective cancer therapy and improved patient prognosis91. As 
CSC are postulated to have a slow rate of division and efficient efflux pumps capable of 
removing toxic agents, traditional chemo- and radiation therapies become inadequate in 
targeting CSC without off-target effects on healthy tissues91. Despite these limitations, 
conventional therapy remains the first line of treatment and often results in cancer 
recurrence due to a residual CSC subpopulation91. A subsequent study conducted by Croker 
et al investigated the role of stem-like ALDHhiCD44+ breast cancer in therapy resistance. 
By inhibiting ALDH enzymatic activity, CSCs became transiently sensitized to 
chemotherapy (doxorubicin/paclitaxel) or radiotherapy measured by decreased cell 
viability and colony formation in vitro93. Moreover, therapy resistance was attributed to 
ALDH activity in part by the ALDH1A1 isoenzyme, and not ALDH1A3, demonstrated by 
siRNA knockdown in vitro92. These findings suggest ALDH activity is an important 
mediator of CSC therapy resistance, and has since been supported by several studies 
reporting similar sensitization through ALDH inhibition94,95. Interestingly, a recent study 
by Yang et al demonstrated that ALDH1A1 overexpression directly correlated with 
increased activity of multidrug efflux pumps through phosphorylation by NIMA-related 
kinase 2 (NEK2)96. An increase in efflux pump activity could support CSCs with high 
ALDH activity to remove therapeutic toxins and allow the tumourigenic cell to continue 
through to metastasis. Considering the importance of ALDH to drug resistance, without 
ALDH inhibition in CSC subpopulations, tumorigenic cells remain resistant to therapy and 
could be detrimental to patients as metastasis persists. 
Taken together, the importance of CSC throughout metastatic progression is well-
supported.  ALDH activity appears to provide CSCs with the capacity to support individual 
steps of the metastatic cascade with regards to extravasation, migration, invasion, and 
colony formation. Moreover, the function of ALDH in therapy resistance also promotes 
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metastasis as CSCs become less likely to undergo apoptosis in response to therapy. Despite 
their supportive role in the cancer progression, transient activation and inactivation of 
cellular processes by CSCs is required to complete the metastatic cascade, suggesting CSC 
plasticity as a key contributor to metastasis. 
 Plasticity of Stem-Like Cancer Cells 
It is generally believed that normal development is largely unidirectional, where slow-
proliferating stem cell populations gives rise to highly proliferative progenitor cells, 
ultimately producing terminally differentiated mature cell types that regulate organ 
function97. The unidirectional nature of the cellular maturation process allows distinct cell 
types with varying specialties to be present within a single organ system and maintain 
functional homeostasis throughout the organisms lifespan97. This is especially clear in 
organs such as the heart, where the annual cardiac myocyte turnover rate is ~1% per year 
at age 20, drastically decreasing to ~0.4% after the age of 7598. That is not to say every 
post-mitotic mature cell is incapable of proliferation. Within the pancreas, mature 
pancreatic β-cells have been reported to expand their population through self-duplication 
as opposed to stem-cell differentiation99. Instances such as self-duplication suggest mature 
cells may have alternative options related to cell fate, despite having undergone terminal 
differentiation. In particular, the concept of cell plasticity has received much attention 
recently as it supports the notion that a cell can alter its phenotype or behaviour in response 
to environmental queues100. The metabolic and epigenetic mechanisms required to induce 
phenotypic plasticity were first documented during early embryogenesis, but have been 
shown to re-activate during normal tissue regeneration, inflammation, and notably during 
tumour development101.  
The re-activation of cellular plasticity in tumour cells has been associated with acquisition 
of a CSC state capable of therapeutic evasion, increased motility, and survival under 
hypoxic conditions101. A prime example of tumour cell plasticity involves the 
aforementioned EMT process. As cells transition from an epithelial state towards a 
mesenchymal phenotype, intrinsic alterations are activated to induce changes in cell 
phenotype and behaviour. In a study conducted by Liu et al, stem-like populations of breast 
cancer cells expressing either a CD44+CD24- or ALDHhi phenotype were found to originate 
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from one patient sample, yet represent two distinct subpopulations of breast CSCs 
expressing mesenchymal-like (EMT) and epithelial-like (MET) phenotypes 
respectively102. Interestingly, the EMT-CSC population was associated with a quiescent 
state and preferentially localized to the invading tumour front, while the MET-CSC 
phenotype was more proliferative and centrally localized102. During tumour development, 
it was initially thought that EMT-CSC mediate invasion into surrounding tissues, while the 
MET-CSCs drive tumour growth internally. As the tumour progresses, CSCs change states 
in order to maintain invasion and proliferation accordingly. These findings suggest that 
plasticity between an epithelial or mesenchymal state in breast CSCs is a transient 
behaviour, rather than a fixed state. Thus, the role of CSC plasticity during tumour 
propagation, invasion, and metastasis is an important consideration in patient treatment. 
Furthermore, plasticity among CSC populations is also evident during therapy. Initially, it 
was postulated that conventional therapeutic agents target and deplete non-CSCs, while 
CSCs evade treatment and expand their population to form a more aggressive tumour upon 
recurrence103. In a recent study conducted by Goldman et al, therapeutic treatment of 
taxanes or anthracyclines on human breast cancer cells in vitro and in vivo not only induced 
apoptosis in the majority of breast cancer cells, but also promoted the transition of non-
CSCs towards a CSC state104. The therapy-resistant cells demonstrated increased 
expression of breast CSC markers (CD44+CD24-) and augmented tumour growth, while 
decreasing survival using patient derived xenograft models in mice. Indeed, these effects 
were not due to an enrichment for the CSC population but rather a transition from non-
CSC to CSC state, demonstrated by the dose-dependent increase of the CSC population 
after acute low dose treatment104. Importantly, the plastic nature of CSCs was demonstrated 
as removal of the chemotherapeutic agent reverted newly generated CSCs back to a non-
CSC state104. CSC plasticity is not specific to breast cancer as similar findings have been 
reported in prostate and ovarian cancer as well103. Nonetheless, the plasticity of the CSC 
state highlights several complexities with regards to the identification of tumourigenic cells 
and their subsequent response to conventional therapies. 
Overall, plasticity among CSC populations plays a significant role in tumour progression, 
metastasis, and therapeutic resistance. Despite the validation of tumourigenic CSCs in 
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several studies, the scientific community has faced difficulties in identifying a universal 
method for identification of elusive CSCs105. This is likely attributed to the search for a 
specific CSC phenotype, rather than a highly plastic subpopulation of tumourigenic cells 
capable of transitioning from one state to another. 
 The “Soil”: Organ Microenvironments 
Cancer metastasis follows an organ-specific pattern of dissemination53. If the metastatic 
site is compatible with the disseminated cancer cells, interactions between these cells and 
the microenvironment will likely promote colonization and secondary tumour formation106. 
Both clinical observation and experimental murine models suggest that organ-specific 
metastasis occurs independent of anatomical position, rate of blood flow, and number of 
cancer cells reaching the organ106. Using radiolabeled melanoma cells, cancer cell 
progression through systemic circulation and successful delivery to key organs was 
monitored after intravenous injection into murine models. Interestingly, radiolabeled 
melanoma cells were selective in colonizing specific organs, demonstrating that although 
tumour cells were capable of reaching the secondary organ, they required a congenial 
microenvironment to support extravasation and tumour development107. More recently, 
high expression of very late antigen 4 (VLA-4) on the endothelial cells surrounding the 
lung, bone, and brain tissue have been demonstrated to support homing of circulating breast 
cancer cells toward these organs through binding of their natural receptor, vascular cell 
adhesion molecule-1 (VCAM-1), aberrantly expressed on the surface of breast CTCs108.  
In our lab, research conducted by Chu et al has demonstrated the role of soluble organ-
derived factors in promoting metastatic behaviour of breast cancer cells using a novel ex 
vivo model system52. Clinically relevant organs representing common sites of breast cancer 
metastasis (lung, bone marrow, liver, brain, LN) were harvested from female nude mice 
and cultured to produce organ-specific conditioned media (CM) for use in functional 
assays. The findings suggested that native soluble factors within organ-CM induced 
chemotactic and proliferative functions among the MDA-MB-231, MDA-MB-468, 
SUM149, and SUM159 human breast cancer cell lines analyzed52,109. Interestingly, these 
patterns of migration and proliferation occurred in a manner that reflected in vivo patterns 
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of metastasis52.  
 The Lung Microenvironment and Lung Metastasis 
The lungs are an indispensable organ involved in respiratory function, mediating the intake 
of oxygen and disposal of carbon dioxide during normal physiological conditions110. The 
functional anatomy of the lungs is divided into two zones. First air enters the conduction 
zone in the upper respiratory tract, travelling down the trachea and directed into each lung 
via the bronchi and terminal bronchioles110. The lower respiratory tract represents the 
respiratory zone, where air is shuttled past the terminal bronchioles and into the respiratory 
bronchioles, eventually reaching the alveolar ducts where individual alveoli necessitate gas 
exchange through an expansive network of capillaries110. Interestingly, the lungs are often 
implicated in various cancers, both as a direct cause from external factors (e.g. chemical 
pollutants) and/or dysregulation of normal physiology111. In particular, the lungs are a 
major site for tumour metastasis of breast and other cancers. A recent investigation of 1,088 
medical records from non-metastatic breast cancer patients between 2004 and 2012 
demonstrated that metastases to the lungs developed in 35% of patients, after a median 
follow-up time of 6.9 years112. Although incidence of breast cancer metastases are higher 
in bone marrow than in lung tissue, tumour formation in respiratory organs severely impact 
the quality of life and are the leading cause of breast cancer related deaths113. Often, the 
more aggressive subtypes such as HER2+ and TN breast cancers metastasize to the lung 
where they largely contribute to impaired respiratory function, leading to intense pain, 
laboured breathing, and often hemoptysis114-117.  
Behind the endothelial-lined capillary networks that supply the lung tissue with nutrients 
and gas exchange, a porous alveolar microenvironment exists that is often targeted by 
CTCs118. Once tumour cells have infiltrated the lung parenchyma, interactions between 
invading tumour cells and the rich stromal microenvironment promote survival and 
tumorigenic behaviour in the cancer cells51. Using a mouse mammary tumor virus 
promoter-polyomavirus middle T-antigen (MMTV-PyMT) breast cancer model, secretion 
of transforming growth factor-β3 (TGF-β3) by stem-like breast cancer cells demonstrated 
direct stimulation of pulmonary fibroblasts to secrete extracellular matrix protein, periostin 
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(POSTN), into the tumour-stroma microenvironment119,120. POSTN is a nonstructural 
soluble protein that is present at low levels in healthy adults, but becomes significantly 
overexpressed at sites of inflammation and within the tumour stroma121. Findings by 
Malanchi et al demonstrate the necessity for POSTN in secondary tumour development as 
knockout of POSTN in PyMT mice had no effect on primary breast tumour size and 
volume, but significantly reduced incidence of pulmonary metastases120. More recently, 
treatment of human periodontal ligament mesenchymal stem cells (PDLSCs) with 
recombinant human periostin protein (rhPOSTN) accelerated migratory and proliferative 
capacity among treated hPDLSCs122. 
Further investigation of the lung microenvironment and its relation to tumour formation 
has been modeled in vivo, however in vitro techniques for more detailed molecular 
characterization of the lung microenvironment are limited as it is difficult to adequately 
represent the complexities of native lung tissue in culture123. Utilizing the aforementioned 
ex vivo model of organ-conditioned media, exposure to lung-CM has been shown to induce 
migration of human breast cancer cell lines, as well as increase proliferative capacity in 
two cell lines, MDA-MB-231 and MDA-MB-46852. In addition, the stem-like 
ALDHhiCD44+ breast cancer subpopulation was exposed to organ-specific CM (bone 
marrow, lymph, liver, lung, and brain) to assess how this subset responded to soluble 
organ-derived factors. Interestingly, ALDHhiCD44+ breast cancer cells were found to 
preferentially migrate towards lung-CM over all other organ conditions in vitro52. These 
findings support observations by Croker et al, where ALDHhiCD44+ breast cancer cells 
were observed to preferentially metastasize to the lung in vivo70. 
To better understand the specific soluble factors within the lung-CM that promote 
migration and growth of breast cancer cells, Chu et al carried out protein array analyses52. 
They observed that lung-CM contained ~70 proteins that were absent in the basal media, 
many of which have previously been shown to have specific roles in metastasis and 
migration 48,49,52. Among the identified proteins, five ligands of CD44 (osteopontin [OPN], 
basic fibroblast growth factor, and E-, L-, P-selectins) were identified to mediate growth 
and metastasis of CD44+ breast cancer cells including stem-like ALDHhiCD44+ cells. 
These findings provided insight to the lung microenvironment and its potential role in 
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recruiting metastasis-initiating cells to the lung. However, little is known regarding the 
processes leading to organ-specific metastasis in the context of the CSC model.  
 The Bone Microenvironment and Bone Metastasis 
In addition to the lungs, bones of the axial skeleton are another major tissue susceptible to 
metastasis in breast cancer patients. Approximately 60-85% of breast cancer patients 
develop bone metastases which significantly affect the integrity and resilience of the bone, 
resulting in chronic pain, bone resorption and pathological fractures in affected patients124. 
Often metastatic colonies form in regions of the skeleton that are heavily vascularized such 
as the pelvis, sternum, ribs, and particularly the marrow of long bones125. Structurally, the 
framework of cancellous bone is organized in a three-dimensional lattice structure, akin to 
lung tissue in that both are porous and supplied by a rich source of nutrients126. What sets 
apart the bone marrow as a metastatic target from other tissues is its ability to support the 
hematopoietic system and related stem cell niche. Within long bones (namely the femur), 
osteoclasts, osteoblasts and bone marrow stromal cells are involved in HSC regulation. 
Osteoblasts are specialized cells involved in the secretion of matrix proteins, and function 
in a coordinated manner with bone-resorbing osteoclasts to maintain physiological 
homeostasis. Interestingly, both cell types have been associated with supporting the HSC 
niche within the marrow. Although somewhat controversial, osteoblasts have been reported 
to interact directly with N-cadherin expressed on HSC to maintain quiescence and HSC 
activity during serial BM transplantation127. Further, activated osteoblasts have been 
demonstrated to secrete OPN, angiopoietin-1, and thrombopoietin, which have been 
implicated in limiting HSC expansion and maintaining quiescence128-130. The active 
resorption of bone by osteoclasts directly releases calcium into the bone marrow where 
calcium receptors on HSCs bind and promote HSC localization through engraftment to the 
endosteal surface of bone131. In addition, resorption of bone causes several chemokines 
secreted by bone marrow stromal cells, such as C-X-C motif chemokine ligand 12 
(CXCL12) which is also involved in HSC homing and mobilization, to be released into the 
marrow132. Conveniently, CSCs from various cancers have been reported to express 
elevated levels of chemokine C-X-C motif receptor 4 (CXCR4), which through interaction 
with its ligand CXCL12, has been implicated in modulating the tumour microenvironment 
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to support a CSC niche133. In a glioblastoma model, inhibition of CXCR4/CXCL12 
interactions led to decreased self-renewal and survival among CSC populations, 
emphasizing the importance of the bone marrow niche in supporting CSC populations134. 
It would be beneficial to achieve a stronger understanding related to the interactions that 
occur between HSC and the native bone marrow microenvironment as these interactions 
may be translatable to CSCs. 
As is the case with the lungs, the complexities of the bone marrow microenvironment make 
it very difficult to accurately investigate its role in cancer metastasis and CSC maintenance 
in vitro, resulting in the majority of research being performed in animal models135. Our 
preliminary findings utilizing the ex vivo organ-CM model demonstrate MDA-MB-231 and 
SUM159 breast cancer cell lines exposed to bone marrow-conditioned media (BM-CM) 
exhibit enhanced migratory potential in both stem-like ALDHhiCD44+ and whole cell 
populations136. Similar to the analysis of lung-CM protein content mentioned previously, 
protein array analysis of BM-CM highlighted potential mediators of metastasis, including 
the CD44 ligand OPN136. Notably, exposure of MDA-MB-231 breast cancer cells to BM-
CM induced stem-like behavior including tumorsphere formation and colony-forming 
ability, mediated at least in part by OPN136. Although present in CM generated from bone 
marrow stromal cells, the bone matrix and cancer cells themselves are also capable of 
producing soluble OPN137. The relevance of OPN to bone metastatic capacity is 
emphasized by experiments utilizing murine models deficient in, or overexpressing OPN, 
where there was a strong correlation between OPN and the likelihood of skeletal 
metastasis137.  
Taken together, our previous findings from both the lung-CM and BM-CM protein arrays 
combined with data gathered from functional assays suggests that proteins produced by the 
lung and bone marrow support the growth and migration of stem-like ALDHhiCD44+ breast 
cancer cells that facilitates their metastatic capacity towards these organs. However, the 
role of these organ microenvironments not only supporting but promoting a stem-like 
breast cancer phenotype requires further investigation, and this is the topic of this thesis. 
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 Study Rationale 
Ninety percent of breast cancer-related mortalities result from metastasis, a process 
whereby the primary tumour disseminates and targets distant secondary organs. 
Interestingly, events leading up to secondary tumour formation have marked inefficiencies, 
with only a very small proportion of primary tumour cells able to reach, persist and grow 
into a secondary tumour138. We believe this rare subset of cells may be stem-like cancer 
cells. CSCs possess unique capabilities of self-renewal and differentiation, and help to 
potentiate the development of secondary tumours. Breast CSCs from patient tumours and 
cell lines have been successfully isolated based on high ALDH enzymatic activity and co-
expression of the cell-surface glycoprotein CD44. These two CSC markers actively provide 
the cell with protective detoxifying mechanisms as well as enhanced metastatic capacity, 
respectively52,76,84. We have previously observed that ALDHhiCD44+ cells preferentially 
migrate and/or metastasize to the lung and bone marrow microenvironments, where 
secondary tumours severely impact organ function. In addition, previous work in our lab 
has demonstrated that bone marrow-conditioned media can enhance the stem-like behavior 
of breast cancer cells. However, the specific role of the lung and bone microenvironments 
promoting metastasis of stem-like ALDHhiCD44+ cells remain poorly understood.  
Our preliminary studies have shown that the lung and bone marrow microenvironments 
provide necessary factors to support the stem-like ALDHhiCD44+ breast cancer 
subpopulation, following a hierarchical model (Figure 1). In this thesis, we propose that 
the lung and/or bone microenvironments may induce cellular plasticity in breast cancer 
cells to promote ALDHhiCD44+ phenotype and subsequent acquisition of metastasis-
initiating capacity (Figure 1). Understanding whether organ microenvironments promote 
stem-like phenotype and function could provide further insight into the mechanisms 
underlying organ-specific breast cancer metastasis. 
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Figure 1. The ALDHhiCD44+ phenotype in breast cancer cells enhances metastasis-
initiating capacity. (A) In the primary breast tumor, ALDHhiCD44+ cells comprise a 
subpopulation of the total tumor; the percentage of which may be higher in aggressive 
tumors (i.e. triple-negative breast cancer). (B) Early dissemination steps in metastasis are 
very efficient and may include both ALDHhiCD44+ and ALDHlowCD44- cells. However, 
only breast cancer cells with an ALDHhiCD44+ phenotype can initiate and maintain 
metastasis. We hypothesize that this may occur either via a hierarchical model, in which 
ALDHhiCD44+ cells are pre-existing before entering the secondary site (i.e. lung) and 
microenvironmental factors support their ability to initiate metastases; and/or via a 
dynamic model, in which the influence of the lung microenvironment may facilitate 
cellular plasticity to promote the development of an ALDHhiCD44+ phenotype and 
acquisition of metastasis-initiating capacity. In both cases the population of ALDHhiCD44+ 
cells are enriched in the metastatic site and can generate a heterogeneous tumor. 
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3 HYPOTHESIS AND OBJECTIVES 
 Hypothesis 
The lung and bone microenvironments promote stem-like and metastatic behavior of 
human breast cancer cells. 
 
 Objectives 
To determine the role of lung and bone microenvironments in promoting (1) stem-like 
phenotype, and (2) stem-like functional behavior of human breast cancer cells in vitro. 
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4 MATERIALS and METHODS 
 Cell Culture and Reagents 
Several genetically unique immortalized human breast cancer cell lines were used in this 
study. The cell lines MDA-MB-468 (TN subtype), SUM159 (TN subtype), MDA-MB-231 
(TN subtype) and MCF-7 (Luminal A subtype) are epithelial in origin and have adherent 
culture properties. The metastatic capacity of these cell lines in vivo (from greatest to least) 
are SUM159 > MDA-MB-231 > MDA-MB-468 > MCF-747,52,139. Human breast cancer 
culturing conditions are described in Table 1. Media was purchased from Invitrogen 
(Burlington, ON, Canada). Fetal bovine serum (FBS) was purchased from Sigma (St. 
Louis, MO, USA) and VWR (Mississauga, ON, Canada). Tissue culture plastic was 
purchased from NuncTM (Fisher Scientific, Ottawa, ON, Canada). Trypsin was purchased 
from Invitrogen and used at a concentration of 0.25% in citrate saline. Ethylene diamine 
tetraacetic acid (EDTA) was purchased from Bioshop Canada Inc. (Burlington, ON, 
Canada) and used at a concentration of 2 mM in deionized water. Cells were cultured at 
low passage numbers (<10) for all experiments and maintained under normal culture 
conditions of 37°C and 5% CO2. 
 Lung and Bone Marrow Ex Vivo Model Systems 
Using a novel technique adapted by Chu et al, lung-CM and BM-CM were generated as 
described below and used to investigate the significance of organ-derived soluble factors 
and their influence on stem-like breast cancer phenotype and function 52,136.  
 Organ Conditioned Media Generation 
Healthy 5-7 week old female athymic nude mice (Hsd: Athymic Nude-Foxn1nu; Envigo, 
Indianapolis, IN) were purchased and monitored under the guidelines of the Canadian 
Council of Animal care as outlined by the protocol approved by the University of Western 
Ontario Council of Animal care (protocol #2009-064; Appendix 1). Mice were euthanized 
by CO2 inhalation and lungs, or tibia and femur were aseptically removed and   
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Table 1. Human Breast Cancer Cell Lines and Culturing Conditions 
Cell Line Culturing Conditions Source 
MDA-MB-468 
 
MDA-MB-231 
 
MCF7 
𝛼MEM + 10% FBS 
 
DMEM:F12 + 10% FBS 
 
DMEM + 10% FBS 
 
MD Anderson 
Cancer Center 
MD Anderson 
Cancer Center 
 
Koropatrick Lab 
SUM159 HAM F:12 + 5% FBS, 0.5% insulin, 
0.1% Hydrocortisone, 1% HEPES  
Asterand 
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placed into pre-weighed 50-mL conical tubes with 30mL sterile phosphate-buffered 
saline (PBS). 
4.2.1.1 Lung Conditioned Media (Lung-CM) 
Harvested lungs were washed three times in ice cold PBS before being dissociated into ~1 
mm3 fragments. Lung tissues were weight-normalized by resuspension in a 4:1 media to 
tissue (v/w) ratio in Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 
(DMEM:F12) supplemented with Mito+ serum extender (1X, BD Biosciences, 
Mississauga, Canada) and penicillin-streptomycin. Lung fragments and media were 
cultured at 37°C and 5% CO2 for 24 hours. Following culturing, conditioned media (CM) 
was harvested, diluted by three volumes of media and centrifuged at 900g for 15 minutes 
at 4°C to remove residual cell debris. Lung-CM was passed through a 0.22μm syringe filter 
(Corning, Germany), aliquoted and stored at -80°C until use. To account for mouse-to-
mouse variability, lung-CM from multiple mice was pooled prior to use in experimental 
studies (Figure 2A). 
4.2.1.2 Bone Marrow Conditioned Media (BM-CM) 
Isolated tibia and femurs from mice were trimmed clean of excess muscle tissue and 
epiphyses removed. Since the cellular content in bone marrow (BM) is lower than in other 
organs, a different approach was used to generate BM conditioned media (BM-CM). Using 
a 27-gauge x ½ inch needle, PBS was flushed through the shaft of each long bone. The 
collected BM cells which had been previously characterized by Chu et al to be bone 
marrow stromal cells (BMSC), were then centrifuged for 5 minutes at 1000g, resuspended 
in DMEM + 10% FBS + pen/strep and incubated at 37°C + 5% CO2. BMSCs were seeded 
at a concentration of ~1 x 107 cells/flask in T-75 flasks and cultured at 37°C and 5% CO2 
for 2-3 passages. The BMSC monolayer was washed and finally exposed to DMEM/F12 + 
Mito+ + pen/strep for 72 hours, after which BM-CM was collected by centrifugation at 
900g for 15 minutes at 4°C, passed through a 0.22μm syringe filter (Corning, Germany) 
and stored at -80°C until use. To account for mouse-to-mouse variability, BM-CM from 
multiple mice was pooled prior to use in experimental studies (Figure 2B). 
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Figure 2. Generation of organ-conditioned media. Healthy female nude mice were 
euthanized by CO2 inhalation and organs were removed aseptically. (A) Harvested lungs 
were washed, minced into ~1 mm3 fragments, and resuspended in a 4:1 media to tissue 
(v/w) ratio for culturing at 37°C and 5% CO2 for 24 h. Following culture, lung-CM media 
is collected and further diluted by three volumes of basal media. (B) Femurs and tibias 
were excised from female nude mice and subject to bone marrow extraction using a 
27gauge x ½ inch needle to flush out the BM contents. Collected cellular bone marrow 
stromal cells (BMSC) were seeded and cultured for 2-3 passages before collection of BM-
CM. All organ-CM is centrifuged to remove cellular debris and subjected to sterile 
filtration prior to use in experimental studies. 
 
 
 
 
 
 
 
 
BM tissue was pushed out from the long bones and 
mechanically disassociated using a 27-gauge x ½ inch needle, 
followed by a 3-week culture period prior to collection. 
Lung tissue was mechanically disassociated using a 
surgical scalpel and cultured in serum free media for 24 
hours prior to collection. 
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 Flow Cytometry Analysis 
Flow cytometry was used to identify the frequency of ALDHhi, CD44+, and 
ALDHhiCD44+cells from both the MDA-MB-468 and SUM159 breast cancer cell lines. 
Initial seeding densities were determined based on 60% tissue culture confluency at a 48-
hour timepoint. MDA-MB-468 (4 x 105 cells) and SUM159 (1.5 x 105 cells) were seeded 
and grown on 60 mm tissue culture dishes in regular growth media for 48 hours. Cells were 
then washed with PBS and exposed to three different treatments: BM-CM, lung-CM, or 
basal media as negative control. Cultured breast cancer cells were harvested using trypsin 
(1x)  after 24, 48, and 72 hours and labeled as described below.  
 
The Aldefluor™ assay kit (StemCell Technologies, Vancouver, BC, Canada) was used to 
assess ALDH activity. The Aldefluor™ kit uses an uncharged fluorescent ALDH substrate 
[BODIPY-aminoacetaldehyde (BAAA)] that passively diffuses into cells. Cellular ALDH 
activity converts uncharged BAAA molecules to negatively charged BODIPY-
aminoacetate (BAA-) molecules, preventing diffusion out of the cell. Trapped BAA- 
molecules increase green fluorescence in ALDHhi cells. Cells were kept on ice prior to 
sorting to prevent the efflux of BAA- from labeled cells by ABC-transporters. In addition, 
the AldefluorTM buffer contains a pharmacological inhibitor of ABC-transporters. 
Approximately 2 x 106 cells were harvested, washed in PBS, centrifuged at 1000g for 5 
min, resuspended in AldefluorTM buffer and incubated with Aldefluor™ substrate (10 µL 
BAAA/106 cells). A control sample was also prepared in which 5 µL the specific ALDH 
inhibitor diethylaminobenzaldehyde (DEAB; 1.5 mM) was co-incubated with Aldefluor™. 
DEAB inhibits ALDH enzyme activity and allows BAAA to remain in its uncharged form 
and passively diffuse out of the cell. Following a 45-minute incubation at 37°C, samples 
were centrifuged (1000g for 5 min), washed with PBS/centrifuged (1000g for 5 min), and 
resuspended with Aldefluor™ assay buffer. Subsequent labelling with 10 µL CD44-
phycoerythrin (PE; BD Biosciences) antibody was performed at 4°C for 30 min. Cells were 
again washed with PBS/centrifuged (1000g for 5 min) and resuspended in assay buffer. 
Following resuspension, 5 µL of 7-aminoactinomycin D (7-AAD; BD Biosciences) was 
added to samples to monitor cell viability. Samples were stored on ice and analyzed by 
30 
 
flow cytometry for intrinsic ALDH activity and/or CD44 cell surface expression using the 
gating strategy illustrated in Figures 3, 4 and 5 (SUM159 cells; adherent MDA-MB-468 
cells; and non-adherent MDA-MB-468 cells, respectively). Analysis was performed using 
a Beckman Coulter FC500 flow cytometer, with acquisition analyses carried out using 
Kaluza 1.5 software (Beckman Coulter, USA). 
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Figure 3. Representative flow cytometry gating strategy for analysis of ALDH activity 
and/or CD44 cell surface expression in SUM159 human breast cancer cells. Whole cell 
populations of SUM159 breast cancer cells were harvested and labelled with 7-AAD, 
CD44-PE, and the Aldefluor™ assay kit. Analysis was performed using a three-colour 
multi-parameter gating strategy on a Beckman Coulter EPICS XL-MCL flow cytometer. 
(A) Viable cells were identified based on 7-AAD exclusion, and (B) gated based on 
forward scatter. Cells satisfying viability criteria were then assessed for (C) ALDH activity 
relative to a DEAB control, and (D) CD44 expression relative to a cells only control. (E) 
Breast cancer cells expressing both high ALDH activity and CD44 expression were used 
to identify the ALDHhiCD44+ phenotype. Analysis performed using 50,000 events.  
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Figure 4. Representative flow cytometry gating strategy for Analysis of ALDH 
activity and/or CD44 cell surface expression in adherent MDA-MB-468 human breast 
cancer cells. Adherent whole cell populations of MDA-MB-468 breast cancer cell lines 
were harvested and labelled with 7-AAD, CD44-PE, and the Aldefluor™ assay kit. 
Analysis was performed using a three-colour multi-parameter gating strategy on a 
Beckman Coulter EPICS XL-MCL flow cytometer. (A) Viable cells were identified based 
on 7-AAD exclusion, and (B) gated based on forward scatter. Cells satisfying viability 
criteria were then assessed for (C) ALDH activity relative to a DEAB control, and (D) 
CD44 expression relative to a cells only control. (E) Breast cancer cells expressing both 
high ALDH activity and CD44 expression were used to identify the ALDHhiCD44+ 
phenotype. Analysis performed using 50,000 events.  
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Figure 5.  Representative flow cytometry gating strategy for analysis of ALDH 
activity and/or CD44 cell surface expression in non-adherent MDA-MB-468 human 
breast cancer cells. Non-Adherent cell populations of MDA-MB-468 breast cancer cell 
lines generated after exposure to organ-CM were harvested and labelled with 7-AAD, 
CD44-PE, and the Aldefluor™ assay kit. Analysis was performed using a three-colour 
multi-parameter gating strategy on a Beckman Coulter EPICS XL-MCL flow cytometer. 
(A) Viable cells were identified based on 7-AAD exclusion, and (B) gated based on 
forward scatter. Cells satisfying viability criteria were then assessed for (C) ALDH activity 
relative to a DEAB control, and (D) CD44 expression relative to cells only control. (E) 
Breast cancer cells expressing both high ALDH activity and CD44 expression were used 
to identify the ALDHhiCD44+ phenotype. Analysis performed using 500,000 events.  
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 RT-qPCR Analysis 
MDA-MB-468 and SUM159 cells exposed to lung-CM, BM-CM, or basal media for 24 
hours were harvested (≤ 5 x 105 cells) and lysed using RLT lysis buffer (Qiagen, Germany). 
Total RNA extraction was performed using a column based RNA purification method 
(RNeasy® Micro kit, Qiagen, Germany). RNA quality and concentration was determined 
using the NanoDrop One apparatus (Thermo Fisher Scientific, USA), and RNA was stored 
at -80°C.  
 Analysis of ALDH1A1, ALDH1A3, and CD44 Gene 
Expression 
Subsequent cDNA synthesis was completed (Invitrogen, USA), combined with 
Supergreen Mastermix (Wisent Bioproducts, CA) and custom primer sets that were 
designed to detect ALDH1A1, ALDH1A3, and CD44 mRNA expression (Table 2). 
Samples were loaded onto 96-well plates and loaded onto the Stratagene Mx3000p 
instrument. The thermal profile setup began at 95 °C for 5 min to allow cDNA to 
denature, followed by 40 cycles at 95 °C for 15 seconds and 60 °C for 30 seconds. 
Relative quantification was performed using a standard curve method with serial dilutions 
(1, 1:10, 1:100, 1:1000, 1:1 x 104). Data were analyzed using ΔCT values and transcript 
levels normalized to the internal control glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). MXPro software (Agilent, CA, USA) was used for qPCR data analysis. 
 Quantitative RT-PCR Human Cancer Stem Cell® Array 
RNA samples from MDA-MB-468 human breast cancer cells were harvested (~5 x 105 
cells) after 24 hour treatment with basal media or lung-CM. Cells were then lysed using 
RLT lysis buffer (Qiagen, Germany), followed by total RNA extraction performed using 
column based RNA purification (RNeasy® Micro Kit, Qiagen, Germany). RNA quality   
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Table 2. Gene List and Primer Sequences 
Gene Primer Sequence Source 
 
ALDH1A1 
 
 
ALDH1A3 
 
 
CD44 
 
 
GAPDH 
 
Forward:   5’ – CGT TGG TTA TGC TCA TTT GGA A – 3’ 
Reverse:    5’ – TGA TCA ACT TGC CAA CCT CTG T – 3’ 
 
Forward:   5’ –  ATG CGG ATT GCC AAA GAG GA – 3’ 
Reverse:    5’ –  AGC CAA CTT CAG GGC TTT GT – 3’ 
 
Forward:   5’ –  GGG TGT ACA TCC TCA CAT CCA A – 3’ 
Reverse:    5’ –  GCT CAC GTC ATC ATC AGT AGG G – 3’ 
 
Forward:   5’ –  TTG CCC TCA ACG ACC ACT TTG T– 3’ 
Reverse:    5’ –  AGG GGT CTT ACT CCT TGG AGG C– 3’ 
 
Integrated DNA 
Technologies (IDT)  
 
Integrated DNA 
Technologies (IDT)  
 
Integrated DNA 
Technologies (IDT)  
 
Integrated DNA 
Technologies (IDT)  
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and concentration was determined using the NanoDrop One apparatus (Thermo Fisher 
Scientific, USA), and stored at -80°C. Subsequent cDNA synthesis was completed using 
the RT2 First Strand Kit (Qiagen, Germany), followed by RT-qPCR preparation using RT² 
SYBR Green ROX qPCR Mastermix (Qiagen, Germany). Samples were then loaded onto 
preset 96-well RT² Profiler™ PCR Array Human Cancer Stem Cells arrays (Qiagen, 
Germany). The thermal setup began at 95 °C for 5 min to allow cDNA to denature, 
followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 30 seconds. RT-qPCR was 
performed on the Stratagene Mx3000p instrument, with analysis of ΔCT values 
performed using MXPro software (Agilent, CA, USA) and Qiagen’s online Data Analysis 
Center. All transcript levels were normalized to the internal GAPDH control. 
 Cell Viability Assays 
 Trypan Blue Exclusion 
MCF7, MDA-MB-468, MDA-MB-231, and SUM159 cells were cultured (37°C, 5% CO2) 
and doubling time was analyzed to determine initial seeding densities that result in 60% 
tissue confluency after 48 hours incubation at 37°C (2 x 105, 1 x 105, 7.5 x 104, and 7.5 x 
104 cells respectively). Cells were seeded on 6-well plates and grown for 48 hours, allowing 
cells to re-adhere and adjust to in vitro conditions. Cells were then washed with PBS x 2 
and exposed to lung-CM, BM-CM, or basal media for an additional 48 hrs. Viability of 
resulting non-adherent breast cancer cell subpopulations was performed by collecting 10 
µL of media and combining with an equal volume of Trypan Blue (1X, St. Louis, MO, 
USA). Total number of cells (live and dead) was enumerated using a hemocytometer under 
a light microscope and percentage of viable cells was determined. Representative images 
of floating and adherent cells were obtained using an inverted Olympus IX70 microscope. 
 LIVE/DEAD® Assay 
Based on trypan blue cell viability analysis, MCF7 and MDA-MB-468 human breast 
cancer cell lines were chosen as candidate cell lines to confirm non-adherent cell viability 
using the fluorometric LIVE/DEAD® assay (Life Technologies, Burlington, ON, CA) 
based on staining with two dyes. Calcein-acetoxymethyl (calcein-AM) is a polyanionic dye 
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that is initially non-fluorescent, but once permeating the cell membrane of viable cells, 
becomes enzymatically converted to its fluorescent form by ubiquitous intracellular 
esterase activity. Conversely, ethidium homodimer-1 (EthD-1) functioned as a marker for 
cell death. In living cells, with a functional plasma membrane, EthD-1 is excluded from 
entering the cell. Once cells become damaged and the plasma membrane’s integrity is lost, 
EthD-1 is able to penetrate and bind to nucleic acids which induce a 40-fold increase in 
fluorescence in dead cells. 
Cells were seeded onto T-75 tissue culture flasks at 3 x 106 and 2 x 106 cells, MCF7 and 
MDA-MB-468 respectively. Cells were cultured for 48 hours, allowing cells to adjust to 
the in vitro conditions. Cells were then washed with PBS x 2 and exposed to lung-CM, 
BM-CM, or basal control media for an additional 48 hours. Media containing non-adherent 
cells were harvested, centrifuged (5 minutes at 1000g), and washed in PBS x 3. The 
collected cell pellet containing non-adherent cells became the experimental sample to be 
tested for viability. From the adherent subpopulation, 2 x 106 viable cells were collected, 
centrifuged (5 minutes at 1000g), washed in PBS x 3, and split into two individual tubes 
labelled “live” and “dead”. The “live” tube provided a positive control. The “dead” tube 
was centrifuged (5 minutes at 1000g) and the cell pellet was treated with 100µL IntraPrep 
Reagent 1: Fixation (IntraPrep Permeabilization Reagent, Beckman Coulter, USA), and 
covered at room temperature for 15 minutes to induce cell death. These “dead” cells 
provided a negative control for the LIVE/DEAD® assay. A working solution of 2 µM 
calcein-AM and 4 µM of EthD-1 LIVE/DEAD® reagent were combined. Using a 96-well 
plate, 100µL of working solution was combined directly with 100µL of sample (1:1) in 
each required well. Samples were covered and incubated at room temperature for 30 
minutes. 
4.5.2.1 LIVE/DEAD® Fluorescent Imaging 
After incubation, 200µL of sample was loaded onto glass microscope slides and covered 
with a 22mm glass coverslip. Images were acquired at 10x magnification using an upright 
Olympus Provis microscope (Olympus) coupled with a Retiga 2000R charge-coupled 
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device camera (QImaging, BC, Canada). Fluorescent images were captured using a Red-
Green-Blue filter fitted to the Retiga 2000R camera. 
4.5.2.2 LIVE/DEAD® Fluorescence Measurement of Viability 
After incubation, the 96-well plate containing samples were inserted into a Synergy H4 
Hybrid Reader (BioTek, USA). Sample excitation/emission (Ex/Em) wavelengths were 
adjusted to 485nm/530nm and 530nm/645nm for each of the live/dead reporters, calcein-
AM and EthD-1 respectively. Sample fluorescence values were recorded and percent 
viability (% Live Cells) was calculated.  
 Mammosphere Assay 
MCF7 and MDA-MB-468 cells were cultured and doubling time was calculated to 
determine initial seeding densities that result in 60% tissue confluency after 48 hours. 
Based on doubling time, 3 x 106 and 2 x 106 cells were seeded on T-75 tissue culture flasks 
(Corning, USA) and cultured for 48 hours respectively, allowing cells to adjust to the in 
vitro conditions. Samples were then washed with PBS and exposed to lung-CM, BM-CM, 
or basal media for an additional 72 hrs. Respective adherent and non-adherent cell 
subpopulations were isolated from each treatment condition and counted manually using a 
hemocytometer and trypan blue exclusion. Approximately 5 x 105 and 3 x 105 viable non-
adherent cells could be expected from each T-75 tissue culture flask following 72-hour 
lung-CM treatment of MDA-MB-468 and MCF7 cells, respectively. Basal and BM-CM 
treatment rendered nearly 1.5 x 105 viable non-adherent cells in either cell line. For each 
subpopulation and treatment condition, 1 x 103 viable cells were resuspended in 
mammosphere media (500mL DMEM:F12, 2.5mL Insulin [1mg/mL], 400µL EGF 
[25µg/mL], 200µL bFGF [25 µg/mL], 20mL of 10% BSA, 2mL B27). Subsequent serial 
limiting dilutions of cells were carried out (1000 cells/well to 0.001 cells/well) and seeded 
onto a 96-well ultra-low attachment plates. Samples were monitored for mammosphere 
growth over 21 days, with media replaced periodically to account for nutrient depletion 
and evaporation. Upon reaching endpoint, an inverted Olympus IX70 microscope was used 
to image and analyze mammospheres. Criteria used to distinguish presence of 
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mammosphere formation was based upon identification of clusters containing ≥ 5 cells. 
Mammosphere formation efficiency was calculated by scoring each well for the presence 
or absence of mammospheres (N=3), with subsequent analyses performed using L-Calc™ 
software (Stem Cell Technologies, Vancouver, BC). 
 Proteomic Analysis of Lung-CM 
Proteomic analysis was carried out by Dr. Ying Xia in the Allan lab, in collaboration with 
Dr. Gilles Lajoie (Department of Biochemistry). Lung-CM samples (N=3) were 
concentrated and fractionated by 1D-SDS-PAGE followed by in-gel tryptic digestion 
before injection into an Ultra-High Performance Liquid Chromatography instrument 
interfaced with a LTQ Orbitrap Elite mass spectrometer (MS). Samples were scanned for 
150 min using the data-dependent acquisition scan mode, selecting the 4 most abundant 
ions from each survey for fragmentation and MS/MS detection, combined with iterative 
exclusion (IE-MS) of previously scanned ions. Raw data was analyzed using “in-chorus” 
protein identification methods employing X!Tandem, SpectraST, and PEAKS search 
engines to allow comprehensive identification and increased statistical confidence in 
independently identified proteins across different platforms. Classification analyses of 
identified lung-CM proteins were performed using the PANTHER® Classification System 
(Geneontology Consortium).   
 Statistical Analysis 
All experiments were performed with at least three biological replicates (N=3), with 
technical replicates (n=3) carried out internally for each biological replicate. Statistical 
analyses were conducted using GraphPad Prism 6.0 (San Diego, CA, USA), with the 
exception of the gene arrays analyzed with Qiagen’s online Data Analysis Center. Data 
were presented as the mean ± standard error of the mean (SEM). A two-way analysis of 
variance (ANOVA) was used to compare multiple means across different groups. Dunnet’s 
post-hoc test was used to confirm significance. Values <0.05 were considered statistically 
significant. 
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5 RESULTS 
 Exposure to lung-conditioned media decreased ALDH activity 
and CD44 expression in human breast cancer cells 
Both the lung and bone have shown high susceptibility to the formation of secondary 
tumours resulting from breast cancer metastasis52,56. Here, we analyze phenotypic 
differences between two different human breast cancer cell lines, including the highly 
metastatic SUM159 (HER2+) and the weakly metastatic MDA-MB-468 (TN) cell lines. 
Assessment of phenotypic variation was assessed by flow cytometry analysis for ALDH 
enzymatic activity and CD44 cell surface expression, producing the ALDHhiCD44+ stem-
like cell phenotype. Contrary to our original hypothesis, 72-hour exposure to lung-CM 
induced a significant decrease in the percentage of adherent cells with ALDHhi and/or 
ALDHhiCD44+ phenotype in both MDA-MB-468 (4.4 ± 2.4%; 4.2 ± 2.1%) and SUM159 
(9.2 ± 0.4%; 9.1 ± 0.4%) cell lines, relative to basal media controls (p<0.05) (Figure 6A 
and B). SUM159 cells showed a significantly decreased ALDHhi and/or ALDHhiCD44+ 
phenotype after 72 hours BM-CM treatment (11.8 ± 0.8 %; 12.0 ± 0.9%) relative to basal 
media controls (p<0.05) (Figure 6B). Further, lung-CM treatment significantly decreased 
CD44 expression in both MDA-MB-468 and SUM159 cell lines (99.1 ± 0.2% and 71.2 ± 
2.1%, respectively), relative to basal media controls (99.7 ± 0.1% and 99.9% ± 0.0%, 
respectively) (p<0.05) (Figure 6A and B). BM-CM had no effect on CD44 expression in 
either cell line.  
 Exposure to lung-conditioned media increased gene expression 
of ALDH1A3 in human breast cancer cells 
Next, we examined mRNA expression for ALDH1A1, ALDH1A3, and CD44 by RT-
qPCR.  In contrast to the flow cytometry results for decreased CD44 expression and ALDH 
activity, both MDA-MB-468 (Figure 7A) and SUM159 (Figure 7B) cell lines exposed to 
lung-CM exhibited significantly increased CD44 (4.0 ± 1.1-fold [MDA-MB-468] and 1.8   
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Figure 6. Exposure to lung-conditioned media decreased ALDH activity and CD44 
expression in human breast cancer cells. (A) MDA-MB-468 and (B) SUM159 cells were 
exposed to lung-conditioned media (lung-CM), bone marrow conditioned media (BM-
CM), or basal media (DMEM:F12 + Mito+) over 72 hours in culture (37°C, 5% CO2) 
without media replacement. Adherent cells were harvested and analyzed by flow cytometry 
for ALDH activity and CD44 expression, using the Aldefluor™ assay and CD44 antibody 
respectively. Experiments were performed a minimum of three times and statistical 
analyses were performed using one-way ANOVA and Dunnett’s post hoc test. Data is 
presented as mean ± SEM. All significant values (*) are relative to the negative control 
basal media treatment group (p<0.05, N=3).  
A 
B 
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Figure 7. Exposure to lung-conditioned media increased CD44 and ALDH1A3 mRNA 
expression in human breast cancer cells. (A) MDA-MB-468 and (B) SUM159 cells were 
exposed to lung-conditioned media (lung-CM), bone marrow conditioned media (BM-
CM), or basal media for 24 hours in culture (37°C, 5% CO2) without media replacement. 
Cells were harvested and RNA was analyzed by RT-qPCR to assess expression of CD44, 
ALDH1A1 and ALDH1A3. All analyses were normalized to GAPDH expression and 
shown as fold-changes relative to basal media (DMEM:F12 + Mito+) controls. Experiments 
were performed a minimum of three times and statistical analyses were performed using 
one-way ANOVA and Dunnett’s post hoc test. Data is presented as mean ± SEM. All 
significant values (*) are relative to the negative basal media treatment group (p<0.05, 
N=3). 
A 
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± 0.2-fold [SUM159]) mRNA expression compared to cells exposed to basal media 
controls (p<0.05). Further, ALDH1A3 mRNA expression was significantly upregulated in 
the SUM159 cell line following treatment with lung-CM (34.9 ± 13.6-fold), relative to 
basal media control (p<0.05) (Figure 7B). Treatment with BM-CM did not lead to 
significant changes in gene expression. Gene expression of ALDH1A1 was not 
significantly affected by organ-CM treatments using either cell line. There was no 
significant difference in relative CD44 mRNA expression levels between either adherent 
or non-adherent MDA-MB-468 cell subpopulations, and the SUM159 cell line, in response 
to basal media (Appendix 3). Moreover, the SUM159 cell line exhibited the lowest 
ALDH1A1 and ALDH1A3 relative mRNA expression levels compared to both adherent 
and non-adherent MDA-MB-468 cell subpopulations following basal media exposure 
(p<0.05) (Appendix 3). 
 Treatment with lung-CM induced a viable, non-
adherent breast cancer subpopulation 
During the course of the phenotypic experiments, we observed that a subpopulation of non-
adherent human breast cancer cells was produced following exposure to lung-CM, and to 
a lesser extent following exposure to BM-CM. Using trypan blue exclusion (Figure 8A), 
we quantified the production of non-adherent cells using four different human breast cancer 
cell lines (MDA-MB-468, MDA-MB-231, MCF7, and SUM159). Surprisingly exposure 
to lung-CM induced a viable non-adherent subpopulation when compared to basal and BM-
CM treatment. Moreover, we demonstrated that the ability of lung-CM to induce a viable 
non-adherent subpopulation was cell line specific, where both of the less aggressive cell 
lines (MCF7 and MDA-MB-468) demonstrated a viable non-adherent subpopulation in the 
presence of lung-CM (10.8 ± 0.9% and 7.5 ± 0.6 % of whole population, respectively) 
relative to basal media (0.3 ± 0.3% and 1.3 ± 0.3 % respectively) (p<0.05) (Figure 8B). In 
contrast, the most aggressive SUM159 cells did not produce a non-adherent subpopulation, 
irrespective of media conditions. Exposure to BM-CM or basal control did not result in a 
prominent non-adherent subpopulation, however, viable non-adherent cells were 
consistently produced among MCF7, MDA-MB-468, and MDA-MB-231 cells exposed to 
BM-CM or basal media. Further analysis was performed using the LIVE/DEAD® assay to  
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Figure 8. Exposure to lung-conditioned media supported the production of viable 
non-adherent breast cancer cells assessed by trypan blue exclusion. MCF7, MDA-MB-
468, MDA-MB-231, and SUM159 human breast cancer cells were exposed to lung-CM, 
BM-CM, and basal media for 48 hours in culture (37°C, 5% CO2) without media 
replacement. Media was collected, centrifuged at 1000g for 5 minutes, and non-adherent 
cells were manually counted using a hemocytometer to assess cell viability via trypan blue 
exclusion. (A) Schematic of experimental approach. (B) Analysis of viable non-adherent 
cells identified in MCF7, MDA-MB-468, MDA-MB-231, and SUM159 human breast 
cancer cells following 48-hour exposure to lung-CM, BM-CM, or basal media. 
Experiments were performed a minimum of 3 times and statistical analyses were performed 
using one-way ANOVA and Dunnett’s post hoc test. Data is presented as mean ± SEM. 
All significant values (*) are relative to the negative control basal media treatment group 
(p<0.05, N=3). 
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quantify viability based on a more sensitive fluorometric approach. Based on trypan blue 
exclusion findings, MCF7 and MDA-MB-468 cell lines were chosen as candidates for 
further analysis. Exposure to lung-CM significantly increased the percentage of viable, 
non-adherent cells produced by both MCF7 and MDA-MB-468 cell lines (11.5 ± 1.2 % 
and 34.9 ± 1.9 % respectively), relative to basal media control (p<0.05) (Figure 9A). 
Further, treatment with BM-CM significantly decreased the viable non-adherent 
subpopulation produced by the MCF7 cell line, but not the MDA-MB-468 cell line. (5.3 ± 
0.1% and 8.8 ± 0.2 % respectively) (p<0.05) (Figure 9A). Both viable and non-viable cells 
were evident through fluorometric analyses (Figure 9B). 
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Figure 9. Exposure to lung-conditioned media supported the production of viable 
non-adherent breast cancer cells assessed by Live/Dead® assays. MCF7 and MDA-
MB-468 human breast cancer cells were exposed to lung-CM, BM-CM, or basal media for 
48 hours without media replacement. Media was collected, centrifuged at 1000g for 5 
minutes, and non-adherent cells were manually counted using a hemocytometer to assess 
cell viability via the Live/Dead® cell viability assay as per the manufacturer’s instructions. 
(A) Analysis of cell viability in non-adherent cells in MCF7 and MDA-MB-468 human 
breast cancer cells following 48-hour exposure to lung-CM, BM-CM, and basal media. (B) 
Representative images (10x magnification) used to carry out fluorometric analysis. 
Experiments were performed a minimum of three times and statistical analyses were 
performed using one-way ANOVA and Dunnett’s post hoc test. Data is presented as mean 
± SEM. All significant values (*) are relative to the negative control basal media treatment 
group (p<0.05, N=3).  
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 Lung-CM and BM-CM reduced CD44 expression, ALDH activity, 
and ALDH1A1 gene expression in non-adherent human breast 
cancer cells. 
Recent evidence suggests the emergence of cancer cell subpopulations with reduced 
adhesive characteristics originating from traditionally adherent breast, ovarian, and colon 
cancer cell lines express heightened tumourigenic capacity, both in vitro and in vivo140,141. 
To assess whether there were differences in ALDH and/or CD44 phenotypes between 
adherent and non-adherent breast cancer cell subpopulations, MDA-MB-468 cells were 
cultured in lung-CM, BM-CM, or basal media for 72 hours, and the non-adherent and 
adherent subpopulations were isolated and analyzed by flow cytometry and RT-qPCR. 
Contrary to our expectations, flow cytometry (Figure 10A) revealed that exposure to lung-
CM significantly decreased ALDH activity and CD44 expression, alone or in combination, 
within the non-adherent subset (57.7 ± 2.5 % [CD44], 6.0 ± 1.1 % [ALDH], and 5.1 ± 0.9 
% [ALDHhiCD44+]) compared to the non-adherent cells exposed to basal media (86.2 ± 
2.9 % [CD44], 28.2 ± 0.9 % [ALDH], 23.3 ± 1.5 % [ALDHhiCD44+]) (β; p<0.05) 
Furthermore, this decrease in ALDH activity and CD44 expression, alone or in 
combination, was also significantly reduced relative to the adherent population exposed to 
basal control media (99.7 ± 0.1 % [CD44], 26.1 ± 1.6 % [ALDH], 27.6 ± 0.2 % 
[ALDHhiCD44+]) (*; p<0.05). Moreover, CD44 expression was significantly decreased in 
non-adherent cells (57.7 ± 2.5 %), compared to their adherent counterpart after exposure 
to the same lung-CM (99.1 ± 0.2 %) (α; p<0.05). Treatment with BM-CM significantly 
decreased CD44 expression in the non-adherent subpopulation (78.3 ± 2.5 %), relative to 
the adherent counterpart receiving the same BM-CM treatment (99.7 ± 0.1 %) (p<0.05). 
There was no effect on ALDH activity, or the ALDHhiCD44+population, after treatment 
with BM-CM (Figure 10A).  
To further investigate phenotypic differences between adherent and non-adherent 
subpopulations after exposure to lung-CM or BM-CM, RT-qPCR analysis was performed 
to assess ALDH1A1, ALDH1A3, and CD44 mRNA expression (Figure 10B). We   
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Figure 10. Exposure to lung-conditioned media reduced CD44 expression, ALDH 
activity, and ALDH1A1 gene expression in MDA-MB-468 human breast cancer cells. 
The MDA-MB-468 human breast cancer cells were exposed to lung-CM, BM-CM, or basal 
media (DMEM:F12) for (A) 72 hours or (B) 24 hours in culture (37°C, 5% CO2) without 
media replacement. Non-adherent and adherent subpopulations were harvested and 
analyzed by (A) flow cytometry or (B) RT-qPCR. Data are presented as mean ± SEM. 
Experiments were performed a minimum of 3 times and statistical analyses were performed 
using a 2-way ANOVA with Dunnett’s post hoc test. Significant values are relative to the 
adherent (*), non-adherent (β) basal media treatment group, or the adherent subpopulation 
of the respective treatment (α) (p<0.05, N=3).  
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observed that ALDH1A1 mRNA expression was significantly decreased after 24-hour 
exposure to both BM-CM or lung-CM (0.4 ± 0.1-fold and 0.5 ± 0.1-fold, respectively), 
relative to basal media (0.8 ± 0.1-fold) (p<0.05). There was no significant difference in 
ALDH1A3 and CD44 mRNA expression between the adherent and non-adherent 
subpopulations exposed to the same organ-CM (Figure 10B). 
 Lung-conditioned media impaired mammosphere formation by 
non-adherent human breast cancer cells. 
To assess whether stem-like function was affected by lung-CM or BM-CM, both adherent 
and non-adherent cell subpopulations were subjected to a limiting-dilution mammosphere 
formation assay. This assay enables the cells either poised for mitotic division or already 
dividing to form non-adherent clusters, using a variety of activated stem cell-associated 
signaling pathways to do so. MDA-MB-468 and MCF7 cell lines were exposed to lung-
CM, BM-CM, or basal media for 72 hours, and the non-adherent and adherent 
subpopulations were plated in limiting dilutions using the mammosphere assay and 
cultured for 21 days. Interestingly, non-adherent MCF-7 and MDA-MB-468 cells were 
incapable of forming mammospheres following exposure to lung-CM (0.0 ± 0.0 freq. and 
0.0 ± 0.0 freq., respectively), relative to the non-adherent subpopulation receiving basal 
treatment (0.008 ± 0.002 freq. and 0.001 ± 0.000 freq., respectively) (p<0.05) (Figure 11A 
and B). Conversely, exposure to basal media or BM-CM supported mammosphere 
formation by both cell lines, irrespective of cell subpopulation. Regarding the adherent 
subpopulations, treatment with organ-CM did not significantly affect mammosphere 
frequency in either MCF7 or MDA-MB-468 cell lines. Further, treatment with BM-CM 
significantly decreased mammosphere frequency among only the non-adherent MCF7 cell 
subpopulation (0.001 ± 0.000 freq.), relative to the non-adherent subpopulation receiving 
basal treatment (0.008 ± 0.002 freq.) (p<0.05) (Figure 11A).  
 Exposure to lung-CM increased mRNA expression related to 
migration and decreased mRNA expression of CSC markers. 
Next, a discovery-based approach was employed to uncover genes affected by lung-CM 
treatment relevant to human CSC function. Both non-adherent and adherent MDA-MB-
468 cell subpopulations were exposed to basal or lung-CM for 24 hours, followed by RT-  
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Figure 11. Exposure to lung-conditioned media impaired mammosphere formation 
by non-adherent human breast cancer cells. (A) MCF7 and (B) MDA-MB-468 human 
breast cancer cells were exposed to lung-CM, BM-CM, and basal media over 72 hours in 
culture (37°C, 5% CO2) without media replacement. Adherent and non-adherent cell 
subpopulations were harvested and viable cells were subjected to a mammosphere 
formation assay over 21 days in culture. Cells were seeded in serial limiting dilution 
fashion onto 96-well ultra-low attachment plates. Mammosphere formation was assessed 
based on the presence or absence of clusters containing ≥ 5 cells per well, followed by 
mammosphere frequency calculated using L-Calc software. Representative images of 
mammospheres formed, or, absence of mammosphere formation by adherent and non-
adherent (C) MCF7 and (D) MDA-MB-468 cell subpopulations. All images were taken at 
10X magnification using an inverted Olympus IX70 microscope. Experiments were 
performed a minimum of 3 times and statistical analyses were performed using one-way 
ANOVA and Dunnett’s post hoc test. Data is presented as mean ± SEM. All significant 
values (*) are relative to the respective basal media treatment in the adherent or 
nonadherent subpopulation (p<0.05, N=3). 
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qPCR analyses. We observed the expression of five genes of interest were affected by 
treatment with lung-CM, relative to basal treatment, including C-X-C Motif Chemokine 
Ligand 8 (CXCL8), Cluster of Differentiation 24 (CD24), Mucin 1 (MUC1), Ataxia 
Telangiectasia Mutated (ATM), and WEE1 G2 Checkpoint Kinase (WEE1) (Figure 12, 
Tables 3,4). Exposure to lung-CM in both adherent and non-adherent subpopulations 
significantly increased gene expression of the metastasis/migration associated gene, 
CXCL8 (19.0 ± 8.8-fold [adherent] and 3.6 ± 1.0-fold [non-adherent]), relative to the same 
subpopulations exposed to basal media (p<0.05) (Figure 12)142. Average Ct values 
between adherent and non-adherent MDA-MB-468 cell subpopulations following 24-hour 
exposure to lung-CM or basal media are provided (Appendix 4). 
Conversely, exposure to lung-CM consistently decreased gene expression of two CSC 
markers, CD24 and MUC1, in both adherent and non-adherent subpopulations (-4.6 ± 0.7-
fold [adherent CD24] and -3.2 ± 0.3-fold [non-adherent CD24]; -2.9 ± 0.6-fold [adherent 
MUC1] and -6.1 ± 0.9-fold [non-adherent MUC1]), as well as two genes related to tumour 
signaling molecules, ATM and WEE1 (-3.5 ± 1.9 fold [adherent ATM] and -4.9 ± 0.3-fold 
[non- adherent ATM]; -2.2 ± 0.2-fold [adherent WEE1] and -4.8 ± 0.7-fold [non-adherent 
WEE1]), relative to the same subpopulations exposed to basal media ( p<0.05) (Figure 
12)143-146.  
 
 Lung-CM contained proteins related to migration, adhesion, and 
stemness 
Finally, mass spectrometry analysis was performed to assess the protein content within 
lung-CM (relative to basal media) in order to gain insight into which effectors may be 
contributing to the observed phenotype and behavior of breast cancer cells. Overall, 1,721 
unique proteins were found in lung-CM. Using the PANTHER® classification system, 
lung-CM proteins were organized based on extracellular (13.4%) or intracellular (86.6%) 
localization (Figure 13A). Among proteins related to the extracellular space, further 
classification was performed to divide proteins based on association with the extracellular 
region (7.4%), membrane-bound proteins (3.5%), cellular junctions (1.3%), and  
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Figure 12. Exposure to lung-conditioned increased mRNA expression related to 
migration and decreased mRNA expression of CSC markers. MDA-MB-468 human 
breast cancer cells were exposed to basal media or lung-CM for 24 hours. Adherent and 
non-adherent subpopulations were harvested and RNA was extracted for use with Human 
Cancer Stem Cell RT2 Profiler PCR
® arrays. (A) Adherent cells exposed to lung-CM versus 
adherent cells exposed to basal media. (B) Non-adherent cells exposed to lung-CM versus 
non-adherent cells exposed to basal media. (C) Non-adherent versus adherent cells exposed 
to lung-CM. The listed genes exhibited a statistically significant and at least 2-fold change 
following normalization to GAPDH (p<0.05, N=3). Analyses were performed using 
Qiagen’s Data Analysis Center® software. 
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Table 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
A = Adherent              NA = Non-adherent 
Table 3. CXCL8, CD24, MUC1, ATM and WEE1 emerge as key genes affected by 
lung-CM treatment. Gene expression analysis was acquired from RT-qPCR of Human 
Cancer Stem Cell® gene arrays. Findings represent differences in gene expression (> 2-
fold) induced by treatment with lung-CM in either adherent or non-adherent 
subpopulations, relative to basal treatment. Arrows reflect direction of gene expression 
fold-change significance. 
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Table 4. Function of CXCL8, CD24, MUC1, ATM, and WEE1. Genes of interest 
were chosen for further characterization based on response to lung-CM treatment, 
irrespective of adherent or non-adherent cell subpopulation. 
Classification Gene of Interest Function 
Migration/Metastasis 
C-X-C Motif Chemokine Ligand 8 
(CXCL8) 
Encodes interleukin 8 (IL8) protein 
expression. As a proinflammatory 
chemokine, IL8 can induce chemotaxis 
of immune-related cells to a target 
site147,148. 
CSC Markers 
Cluster of Differentiation 24 
(CD24) 
CD24 encodes a glycoprotein that is 
anchored via a glycosyl 
phosphatidylinositol (GPI) link to the 
cell surface. CD24 protein functions as a 
cell adhesion molecule, and its loss is 
associated with a stem-like cancer cell 
phenotype62. 
Mucin 1 
(MUC1) 
MUC1 encodes for cell surface 
glycoprotein with an active extracellular 
domain due to O-linked glycosylation. 
The cytoplasmic tail of MUC1 functions 
as an oncoprotein through interactions 
with tumour promoting pathway and is 
often overexpressed in certain cancers. 
The protein can also localize to the 
nucleus for interaction with WNT 
signaling149.  
Tumour Signaling Molecules: 
Cell Cycle Control 
Ataxia Telangiectasia Mutated 
(ATM) 
ATM encodes for serine/threonine 
kinase, which belongs to the PI3/PI4-
kinase family. Together with ATR, ATM 
is considered a master regulator of cell 
cycle checkpoints. ATM has a central 
role in repair of double-stranded DNA 
breaks150. Further, elevated ATM 
expression has been associated with 
favorable patient prognosis151. 
WEE1 
WEE1 encodes for a nuclear kinase that 
is part of the Ser/Thr protein kinase 
family. Through the inhibition of CDK1, 
WEE1 is a negative regulator of entry 
into mitosis (G2 – M)146. In cancer, 
impaired WEE1 has led to the loss of 
DNA-damage induced apoptosis and 
aberrant mitosis146. 
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Figure 13. Classification of intra- and extracellular proteins found in lung-CM. Mass 
spectrometry analysis (N=3) revealed 1,721 proteins that are unique to the lung-CM 
relative to basal media. (A) Among these proteins, 13.4% are classified as extracellular and 
86.6% are classified as intracellular compartmentalized proteins. (B) Proteins belonging to 
the extracellular compartment are of particular interest as they may be secreted from the 
lung as soluble proteins and impose an effect on human breast cancer cells. Among the 
proteins belonging to the extracellular compartment, further classification associated these 
proteins with the extracellular region (7.4%), membrane-bound (3.5%), cellular junctions 
(1.3%), and extracellular matrix (1.2%). Analyses were performed using PANTHER® 
Classification System software. 
A 
B 
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extracellular matrix (1.2%) (Figure 13B). From the soluble extracellular compartment, 
osteopontin (OPN), periostin (POSTN), a disintegrin and metalloproteinase domain-
containing protein 10 (ADAM10), and β-catenin were of particular interest as they have 
strong associations with cell migration and adhesion pathways136,152-154. Upon analysis of 
the intracellular compartment, several proteins associated with angiogenic VEGF, 
stemness (WNT/NOTCH), and migratory (Ras/Rho) pathways were observed to be 
present155-157.  When assessing proteins related to CD44, ADAM10 was present in the lung-
CM, and absent in the basal media (Table 5, Figure 14A)152. Among intracellular proteins, 
6 proteins were found to be related ALDH/RA signaling pathway (Table 5) including 
retinol binding protein 1 (RBP1), alcohol dehydrogenase 1 (ADH1), aldehyde 
dehydrogenase 1A1 and 1A7 (ALDH1A1 and ALDH1A7), cytosolic retinoic acid binding 
protein 2 (CRABP2) and fatty acid binding protein 5 (FABP5) (Figure 14B)158,159. 
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Table 5. Function of proteins within lung-CM related to ALDH/RA signaling 
pathway and CD44 cleavage. 
Potential Interaction with: Proteins of Interest Function 
ALDH/RA  
Pathway 
Retinol Binding Protein 1 
(RBP1, CRBP1) 
Involved in retinol transport once the 
vitamin A alcohol has entered the cell 
(functions intracellularly)160. 
Retinol Binding Protein 4 
(RBP4) 
Major role in retrieving retinol from liver 
storage, and transporting to peripheral 
tissue through systemic circulation 
(functions within blood plasma)161. 
Alcohol Dehydrogenase 1 
(ADH1) 
Enzyme involved in oxidation of retinol 
to retinal, an aldehyde. Required for 
clearance of excess retinol, which could 
result in retinol toxicity162. 
Aldehyde Dehydrogenase 1A1 
(ALDH1A1) 
Enzyme responsible for the further 
oxidation of retinal to retinoic acid (RA). 
Enzyme activity has significant 
implications regarding tumour 
development and stem cell 
maintenance92. 
Aldehyde Dehydrogenase 1A7 
(ALDH1A7) 
ALDH1 family isoenzyme involved in 
RA synthesis. Has been associated with 
olfactory and respiratory tissues163.  
Cytosolic Retinoic Acid Binding 
Protein 2 
(CRABP2) 
Binds to, and translocates RA into the 
nucleus for activation of RAR/RXR 
transcription machinery159. 
Has anticarcinogenic effects associated 
with cell apoptosis, differentiation, and 
growth arrest159. 
Fatty Acid Binding Protein 5 
(FABP5) 
Can also bind to RA and translocate into 
the nucleus for activation of PPAR 
pathway159. 
Has procarcinogenic effects associated 
with cell survival and proliferation159. 
CD44 Cell Surface Expression 
Disintegrin and Metalloproteinase 
Domain-containing Protein 10 
(ADAM10) 
ADAM10 is a proteolytic enzyme that is 
capable of preferentially cleaving 
CD44152. 
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Figure 14. Mass spectrometry analysis of lung-CM identifies key proteins related to 
the ALDH/RA and CD44 pathways. Mass spectrometry analysis was carried out to 
investigate proteins contained with the lung-conditioned media and their potential 
relationship with the phenotypic and functional behavior of breast cancer cells. (A) The 
CD44-related disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) 
cleaves CD44 at the extracellular ectodomain. (B) Several proteins relevant to the 
ALDH/RA pathway (labelled in red) were found to be present within the lung-CM. Those 
proteins included: retinol binding protein 1 and 4 (RBP 1 + 4), alcohol dehydrogenase 1 
(ADH 1), aldehyde dehydrogenase 1A1 and 1A7 (ALDH1A1 and ALDH1A7), cytosolic 
retinoic acid binding protein 2 (CRABP2), and fatty acid binding protein 5 (FABP5). There 
may be a potential mechanism for these soluble proteins to be internalized by cancer cells 
and utilized as exogenous machinery.  
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6 DISCUSSION 
Among Canadians, the mortality rate associated with breast cancer has declined by 44% 
since its peak in 19861. Such a drastic decrease can be attributed to improved early-stage 
tumour detection, by government-funded mammography screenings, made readily 
available to Canadians in 1992164. Although mortality rates have decreased, the incidence 
rates have not decreased. Since 1988, the age-standardized incidence rates have remained 
high among women and seen little change in this trend as of late1. This stagnant incidence 
rate has maintained breast cancer’s position as the third most common cancer among 
Canadians, making up 13% of all cancers and 25% of cancers in women1. What is more 
dismal, after receiving adjuvant chemotherapy for the primary tumour, patients who 
developed metastatic disease within 10 years of treatment were met with a near 
unanimously fatal outcome, a statistic that has not changed in the last 30 years165.  
 
Breast cancer is currently a treatable disease, but a lack of effective therapies in the 
metastatic setting render breast cancer largely incurable once the cancer has disseminated 
beyond the breast. This is due in part to tumour heterogeneity which has presented a major 
obstacle for the research and clinical communities, making cancer biology complex and a 
generic treatment regimen difficult to achieve166. For patients with endocrine-responsive 
tumours, hormonal therapy has demonstrated modest improvements in overall patient 
survival167. When endocrine-receptors are absent, hormonal therapy becomes ineffective, 
and systemic chemotherapy is necessary to target a wide range of rapidly proliferating cell 
types167. Often, tumourigenic cells acquire resistance to primary treatment strategies and 
become resistant to therapy, allowing the metastatic processes to persist166,167. The issue 
concerning current therapies is that they do not eradicate all cancer cells within a patient, 
neglecting cells that may exhibit a decreased rate of proliferation. The emerging CSC 
model suggests that a rare population of slow-proliferating, tumourigenic cells are capable 
of repopulating a heterogeneous tumour and contribute to disease recurrence and evasion 
of conventional therapies168. Several studies have identified subpopulations of potential 
stem-like cancer cells using traditional stem cell markers, such as ALDH, alone or in 
combination with different intrinsic and extrinsic factors. In breast cancer, stem-like cells 
have been phenotypically identified as having high enzymatic ALDH activity and CD44 
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cell surface expression, however targeted treatments have been unsuccessful due the 
transient and dynamic phenotype of stem-like cancer cells61,62,169. Understanding the role 
of stem-like and/or metastasis-initiating cancer cells during tumour progression and/or 
metastatic development is critical for establishing effective treatment strategies to target 
these rare and aggressive populations.  
 
The significance of CSCs in breast cancer metastasis and secondary tumour formation is 
important to consider in the context of preferential patterns of organ tropism. Massagué 
and colleagues contributed significantly to knowledge about organ-specific breast cancer 
metastasis when they observed that intrinsic genes within breast cancer cells can mediate 
metastasis to the lung, bone marrow, and brain47-49. Although profound, these findings did 
not address the role of the organ microenvironment, nor the role of CSCs in organ tropism 
of breast cancer metastasis. Efforts in our laboratory aimed to address these voids by 
demonstrating the potential for soluble proteins generated by the lung and BM 
microenvironments to promote migratory and proliferative behaviour in stem-like 
ALDHhiCD44+ breast cancer cells in vitro, and increased incidence of spontaneous 
metastasis of these stem-like cells to lung in vivo 52,70,136. These initial investigations 
suggested a role for the lung and bone marrow microenvironments in supporting growth, 
migration and metastasis of ALDHhiCD44+ breast cancer cells. However, it was unclear 
whether the lung and/or bone microenvironments could additionally promote the 
acquisition of a stem-like phenotype and function within breast cancer cell populations, 
and this thesis focused on this question. We utilized an ex vivo model of lung- and bone-
conditioned media and hypothesized that exposure to these lung or bone 
“microenvironments” would increase the proportion of breast cancer cells expressing the 
stem-like ALDHhiCD44+ phenotype and enhance stem-like cell behaviour.  
 
 Summary of Key Experimental Findings 
The key experimental findings of this thesis are summarized in Table 6 and listed below.  
1. Exposure to lung-CM decreased the frequency of MDA-MB-468 and SUM159 
breast cancer cells expressing the stem-like ALDHhiCD44+ phenotype.  
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2. Exposure to lung-CM increased the frequency of a viable, non-adherent 
subpopulation in MDA-MB-468 and MCF7 human breast cancer cells. 
3. Exposure to lung-CM decreased CD44 expression in non-adherent MDA-MB-468 
human breast cancer cells. 
4. Exposure to lung-CM impaired mammosphere formation by non-adherent MDA-
MB-468 and MCF7 human breast cancer cells. 
5. Lung-CM contained proteins related to migration, adhesion, and stemness. 
6. Exposure to lung-CM resulted in increased mRNA expression related to migration 
and decreased mRNA expression of “cancer stem cell (CSC)” markers. 
  
Table 6. Summary of results assessing adherent and non-adherent cell subpopulations 
treated with BM-CM or lung-CM. 
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 Lung-CM inhibits stem-like phenotype and behaviour in 
adherent human breast cancer cells 
Contrary to expectations, we observed that exposure of MDA-MB-468 and SUM159 breast 
cancer cells to lung-CM decreased the proportion of cells expressing an ALDHHiCD44+ 
phenotype. Of the parameters that comprise our chosen stem-like phenotype, ALDH 
activity was significantly decreased in response to lung-CM treatment in both cell lines, 
while CD44 expression was only decreased in the SUM159 cell line. Treatment with BM-
CM also decreased the ALDHHiCD44+ phenotype, however, this decrease was modest in 
comparison to lung-CM. This discovery was unanticipated given that lung and BM tissue 
are highly targeted sites of metastasis, together with accumulating evidence suggesting that 
ALDHhiCD44+ cells play a key role in driving breast cancer progression52,72,170,171.  
 
To further investigate the influence of lung-CM, we performed mRNA analysis of CD44, 
and two major ALDH isoenzymes, ALDH1A1 and ALDH1A372. Due to the inherent delay 
associated with gene transcription prior to achieving functional protein, RT-qPCR analysis 
was performed after 24-hour exposure to organ-CM. Interestingly, mRNA transcription 
analyses demonstrated a significant upregulation of CD44 mRNA expression after 24-hour 
treatment with lung-CM, in both MDA-MB-468 and SUM159 cell lines. This increase in 
CD44 mRNA expression was not consistent with our flow cytometry results measuring 
decreased CD44 cell surface expression. This is not surprising as CD44 cleavage often 
occurs at the cell surface during locomotion and migration, suggesting a potential positive 
feedback system driving CD44 mRNA expression following treatment with lung-CM.172 
Further, ALDH1A3 mRNA expression was also increased following treatment with lung-
CM in the SUM159 cell line only. As ALDH activity was largely decreased by lung-CM 
treatment following flow cytometry analysis, this warranted further investigation to 
measure ALDH protein level. However, western blot analysis of ALDH1A3 protein did 
not indicate a significant difference in protein levels between basal media and lung-CM 
treatments, suggesting potential post-transcriptional or post-translational modifications 
that may interrupt the production of functional ALDH1A3 enzyme (Appendix 2). In the 
future, further analysis of terminal protein localization and the extent of ubiquitination on 
the ALDH1A3 protein may help better understand the opposing data (e.g. whether proteins 
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are destined for lysosomal degradation)173. Another factor that may contribute to a loss of 
ALDH activity is stem cell differentiation or maturation. Although high ALDH activity is 
associated with the detection of a stem-like phenotype, ALDH can induce differentiation 
through the production of RA and subsequent downstream signaling pathways. Therefore, 
treatment with lung-CM could induce stem-like cells to differentiate, resulting in decreased 
ALDH activity. In a recent study, Muramoto et al found that inhibition of the ALDH1 
enzyme impeded the differentiation of murine hematopoietic stem cells (HSCs), resulting 
in a 9-fold expansion of radioprotective cells174. These HSCs both maintained their stem-
like state and maintained radioprotection through inhibition of ALDH activity. Another 
study performed by Hessman et al demonstrated that decreased ALDH1 protein expression 
in primary and metastatic colorectal cancer samples correlated with advanced and 
metastatic cancers, while high ALDH1 expression was associated with non-metastatic 
tumours175. Together with findings in the literature, our recent data suggests a loss of stem-
like phenotype could result in increased metastatic capacity. 
In addition to phenotypic analysis by flow cytometry, the enrichment of stem-like cells 
through spheroid formation has become a useful technique to measure stem-like behavior 
of cancer cell populations. Introduced in 1992 by Reynolds and Weiss to assess 
proliferation, self-renewal, and multipotency of neural precursor cells, the neurosphere 
assay has since been repurposed for use in a variety of models, particularly CSC biology176. 
Adapted by Dontu and colleagues, the mammosphere assay utilizes non-adherent and non-
differentiating culture conditions to evaluate individual breast cancer cells on their ability 
to self-renew/proliferate in suspension, forming multicellular mammospheres in vitro177. 
In the current study, we set out to investigate the mammosphere-forming capacity of 
adherent MCF7 and MDA-MB-468 human breast cancer cells after exposure to lung- or 
BM-CM. We did not observe a significant effect on mammosphere formation frequency in 
either adherent MCF7 or MDA-MB-468 cells following exposure to lung-CM or BM-CM. 
Both cell lines were capable of forming mammospheres irrespective or organ-CM received, 
suggesting that factors within the lung-CM or BM-CM did not interfere with stem-like 
functions such as mammosphere formation among the adherent cell subpopulation.   
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Taken together, exposure to lung-CM decreased the proportion of cells expressing the 
stem-like ALDHhiCD44+ phenotype, however did not affect functional stem-like behaviour 
of human breast cancer cells. This suggests that the lung microenvironment does not 
promote stem-like phenotype in adherent breast cancer cells, and instead, may inhibit it.  
 Lung-CM induced a viable, non-adherent breast cancer cell 
subpopulation with decreased stem-like phenotype and function 
During the course of our studies, we qualitatively observed that exposure to lung-CM 
induced a non-adherent breast cancer cell subpopulation. Both the MDA-MB-468 and 
SUM159 cell lines have been characterized as adherent in culture, leaving the possibility 
of a thriving non-adherent subpopulation among these cells unlikely178,179. Interestingly, 
upon trypan exclusion analysis, a viable, non-adherent MDA-MB-468 subpopulation was 
confirmed after exposure to lung-CM. This finding was not nearly as pronounced after 
either BM-CM or basal control treatments, and completely absent in the more metastatic 
SUM159 cell line, irrespective of organ-CM. Since only the MDA-MB-468 cell line 
produced a non-adherent subpopulation, we performed a screening of two additional 
human breast cancer cell lines, MDA-MB-231 and MCF7, to assess if other traditionally 
adherent cell lines would generate a similar non-adherent subpopulation following 
exposure to lung-CM. Both additional cell lines produced a non-adherent subpopulation, 
however of the four cell lines tested, the least aggressive MCF7 and MDA-MB-468 cell 
lines most efficiently produced viable, non-adherent cells. We next performed a 
LIVE/DEAD® viability assay on the two candidate cell lines, MDA-MB-468 and MCF7 to 
confirm our trypan exclusion results. Upon fluorometric analysis, both MDA-MB-468 and 
MCF7 cells demonstrated a significant increase in viable, non-adherent cells after lung-
CM treatment. The observation that the induction of viable non-adherent cells was most 
pronounced after treatment with lung-CM suggests that components of the lung 
microenvironment may interact with adherent breast cancer cells in a manner that induces 
cell detachment.  
To accurately compare differences between the stem-like phenotype of adherent and non-
adherent breast cancer cell subpopulations, we performed additional flow cytometry 
analyses to assess ALDH activity and CD44 cell surface expression after treatment with 
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organ-CM. Again unexpectedly, we observed that exposure of the non-adherent MDA-
MB-468 cell subpopulation to lung-CM further decreased CD44 expression relative to the 
adherent subpopulation, while ALDH activity, and the proportion of cells expressing the 
stem-like ALDHhiCD44+ phenotype, remained relatively low and unchanged between both 
adherent and non-adherent subpopulations. When comparing BM-CM treatment between 
adherent and non-adherent MDA-MB-468 cells, we also observed a decrease in CD44 
expression within the non-adherent subpopulation, yet this decrease was limited in 
comparison to the lung-CM response. Consistent with our analyses of protein expression, 
gene expression analysis revealed that ALDH1A1 gene expression in the non-adherent 
MDA-MB-468 subpopulation was significantly downregulated after exposure to both 
lung- and BM-CM. Thus, while the proportion of non-adherent and adherent cells 
expressing the stem-like ALDHHiCD44+ phenotype was largely unaffected, CD44 
expression was consistently decreased in the non-adherent cell subpopulation relative to 
the adherent counterpart, especially after treatment with lung-CM. In a recent study by 
Ngan et al, loss of E-cadherin and CD44 expression were significantly correlated with poor 
survival in colorectal cancer patients180. In addition, a study conducted by Sugino et al 
demonstrates that a loss in CD44 expression resulted in tumour cell detachment from the 
basal membrane, and subsequent invasion by cancer cells181.  
Next, we wanted to address potential differences in stem-like function between non-
adherent and adherent breast cancer cell subpopulations after exposure to organ-CM. 
Research published by House et al demonstrated a non-adherent subpopulation in both 
ACI-23 and OVCAR-5 human ovarian cancer cell lines that more readily produce 
spheroids in vitro, and larger tumours in vivo140. Furthermore, a Morata-Tarifa et al found 
trypsin sensitive (non-adherent) human breast and colon cancer cells demonstrated 
increased sphere-forming capacity in vitro, when compared to their trypsin-resistant 
(highly adherent) counterparts141. We performed a similar experiment whereby we exposed 
adherent and non-adherent subpopulations of both MDA-MB-468 and MCF7 breast cancer 
cells to organ-CM, and subjected them to the mammosphere formation assay in limiting 
dilutions. Contrary to the findings of House et al Morata-Tarifa et al, our data does not 
demonstrate increased mammosphere formation by non-adherent cells. Instead, we 
observed that treatment with lung-CM significantly impaired mammosphere formation in 
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both cell lines, while treatment with BM-CM decreased mammosphere formation in non-
adherent MCF7 cells. Interestingly, both MCF7 and MDA-MB-468 non-adherent cell 
subpopulations exposed to lung-CM were incapable of forming mammospheres after 21 
days in culture. As a cell adhesion molecule, CD44 expression is significant in making 
cell-cell and cell-ECM interactions. Ponti et al demonstrated the necessity for CD44 
expression in successful mammosphere formation when they documented 95-96% of cells 
within mammospheres derived from MCF7 and three primary cells lines were 
CD44+/CD24-182. Their findings suggest that the inability of our non-adherent breast cancer 
cells to form mammospheres could be attributed to the observed loss of cell surface CD44 
expression. Taken together with our previous studies and our observations here that the 
non-adherent breast cancer subpopulation was less stem-like than the adherent 
subpopulation in the presence of lung-CM, our findings suggest that while CD44 and 
stemness are likely important for the earlier steps of metastasis, they may not be necessary 
once breast cancer cells become established in the lung microenvironment52,70.  
 Lung-CM contained proteins related to migration, adhesion, and 
stemness  
Distant metastases account for nearly 90% of cancer-related deaths, yet the processes 
leading to the development of distant tumours is the most poorly understood aspect of 
cancer pathogenesis183,184. Accumulating data now suggests that breast cancer, leukemia, 
sarcoma, and kidney cancer have a preferential pattern of metastasis towards the lung 
tissue, while other cancers affecting the colon, head-and-neck, and pancreas also reach the 
lungs, but in a non-specific manner118,185. The lung microenvironment is composed of 
insoluble and soluble components, both of which have unique roles in tumourigenesis. The 
insoluble lung microenvironment is composed of several structural ECM proteins such as 
collagens, elastin, fibronectin, laminin, and proteoglycans that together, represent nearly 
65% of the lung tissue186-188. The majority of tissue infrastructure in the lung is provided 
by these ECM components, and often commandeered by tumour cells as the porous and 
elastic environment is well suited for metastatic colonization189-191. Similar to the insoluble 
lung microenvironment, ECM components such as collagens, fibronectins, and laminins 
are present in varying levels within the insoluble structures of cancellous bone 
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matrices192,193. Considering these similarities, investigation of the soluble lung 
microenvironment could provide insight relative to the insoluble component. Composed of 
more than 60 cell types, a variety of unique secretions are produced by cells of the lung 
which may have a pivotal role in mediating preferential metastases194. Findings by Chu et 
al and Pio et al demonstrated that soluble proteins within the lung and BM 
microenvironments induced preferential migration in a chemotactic manner. In particular, 
both studies noted an increased migratory capacity among the stem-like ALDHhiCD44+ 
breast cancer cell population towards both lung and BM microenvironments, supporting 
Croker et al finding of increased spontaneous metastases by ALDHhiCD44+ breast cancer 
cells to the lung in vivo52,70,136. To begin to uncover potential mechanisms that may be 
involved in preferential metastases to the lungs, our goal was to start to investigate the 
composition of lung-CM and assess how this may be influencing stem-like phenotype and 
characteristics of human breast cancer cells. 
Investigation of our lung-CM treatment was initiated by Chu et al. through protein array 
analysis. Over 70 unique proteins were observed in the lung-CM that have an association 
with migration, proliferation, adhesion, and metastasis52. Much of this work highlighted 
the role of the lung microenvironment as a chemoattractant, where OPN was suggested to 
have significant roles in breast cancer migration towards the lungs52. To provide a more 
unbiased analysis of the composition of lung-CM, we utilized mass spectrometry and found 
a total of 1,721 soluble proteins unique to the lung-CM, that were absent in the basal 
treatment. The clear majority, 86.6%, were intracellular-derived proteins, likely originated 
from the lung tissue as an artifact of the dissociation process required to cultivate lung-
CM. The remaining 13.4% of proteins belong to the extracellular compartment, making 
this proportion of proteins a key area for investigation. As our treatment conditions 
required human breast cancer cells to be cultured with organ-CM, proteins that would 
normally be associated with the extracellular space in vivo are prone to interact with seeded 
breast cancer cells in vitro. Among the proteins identified, key mediators of migration and 
adhesion including OPN, POSTN, ADAM10, and β-catenin were present.  
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 Osteopontin 
Confirming findings by Chu et al, lung-derived OPN was present in the lung-CM and has 
been previously been implicated in cell-matrix interactions that promote cell motility, 
invasion, and angiogenesis195-197. Using a melanoma model, Kumar et al found the 
knockout of OPN in mice decreased tumour growth, impaired angiogenic processes, and 
stunted metastatic potential195. Findings by Pio et al also support the importance of BM-
derived OPN in promoting breast cancer cell migration and mammosphere formation in 
vitro among whole cell and stem-like ALDHhiCD44+CD24- breast cancer cell 
populations136. Moreover, experiments involving exogenous overexpression of OPN have 
demonstrated its role as a negative regulator of HSC self-renewal and localization within 
BM, while OPN-null mice displayed a clear expansion of the HSC population in murine 
BM130,198. With lung-derived OPN present within lung-CM, the negative regulation of HSC 
maintenance by OPN suggests this function could potentially extend to CSC regulation, 
inhibiting expansion of stem-like cells when OPN is present within the microenvironment. 
Thus, OPN’s association with metastatic processes and regulation of stem cell fate may 
contribute to the reduction in ALDHHiCD44+ phenotype and stem-like function 
demonstrated in our study.  
 Periostin 
With implications in tumourigenesis, the identification of POSTN within lung-CM is also 
an interesting finding as its secretion has been found to originate from both tissue stromal 
cells and infiltrating cancer cells120. Abnormally high levels of POSTN have been reported 
both experimentally and clinically in various cancers of the breast, ovary, and liver199,200. 
In the pulmonary tissue, lung fibroblasts secrete POSTN into the extracellular space to 
transmit signals from the ECM to cells via interactions with surface receptors such as 
integrins, mediating cell motility, adhesion, and proliferation201. It is well documented that 
POSTN promotes tumour cell invasion and metastasis through the integrin/PI3/AKT 
pathway, promoting the development of various cancers153,202. In particular, POSTN 
interaction with integrin αvβ3 expressed on the endothelium of alveolar micro-vessels cells 
has been shown to mediate fibroblast or malignant cell migration203,204. Sasaki et al utilized 
in situ RNA hybridization to identify high POSTN gene expression was not occurring from 
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within the breast cancer cells, but instead originating from stromal cells directly adjacent 
to the bulk tumour205. Although many studies postulate the source of POSTN being the 
cancer cell, very few cancer cell lines have demonstrated significant POSTN mRNA levels 
in vitro, suggesting that stroma-derived POSTN may be of interest during 
tumourigenesis206. The finding that lung-CM contains POSTN derived from the pulmonary 
stroma suggests that its presence could be a factor that promotes metastasis and suppresses 
stem-like characteristics.  
 β-Catenin 
The presence of β-catenin within the lung-CM is worthy of further investigation as it has 
been implicated as a factor involved in determining stem cell fate207,208. Regulated by 
extracellular Wnt ligand interactions with the Frizzled receptor family, the canonical 
Wnt/β-catenin signaling pathway allows for the intracellular accumulation of β-catenin 
resulting in induction of stem cell differentiation209. Aberrant fluctuation of cytosolic β-
catenin has been associated with malignancy in various organs, and several studies report 
that basal-type TN breast cancers expressing unusually high levels of β-catenin have worse 
overall survival154,210,211. Although its production occurs intracellularly, recent findings 
have demonstrated that β-catenin can be packaged in exosome-like vesicles and transported 
into the extracellular space or circulation212,213. Further, Dovrat et al demonstrated that 
human embryonic kidney cells (HEK293) not only produced extracellular vesicles 
containing β-catenin, but that these vesicles were prooncogenic as the adjacent target cells 
receiving the exosome translocate β-catenin to the host nucleus and activates Wnt-
stimulated transcription212. Since our model of the lung microenvironment involves 
mechanical dissociation of murine lung tissue, if exosomal structures containing β-catenin 
had formed, such a vesicle could be lysed and its contents released into the lung-CM for 
interaction with human breast cancer cells in vitro. Thus, potential uptake of β-catenin by 
human breast cancer cells could lead to accumulation within the cell, activating canonical 
Wnt signaling to induce differentiation among CSCs, resulting in a decreased stem-like 
ALDHhiCD44+ phenotype.  
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 Proteins that Influence Cell Detachment and Extracellular 
Transport 
To address the potential role of the lung microenvironment in mediating the transition of 
adherent human breast cancer cells into a non-adherent subpopulation, both β-catenin and 
ADAM10 have demonstrated mechanisms involved in cellular detachment. With the 
possibility that β-catenin internalization by breast cancer cells could have potentially 
occurred in our ex vivo model, previous studies have shown that β-catenin overexpression 
in Madin-Darby Canine Kidney (MDCK) cells induced a transformation of these 
traditionally highly adherent epithelial cells towards a mesenchymal phenotype with 
distinct cellular extensions214. Furthermore, several studies have confirmed that MDCK 
cell survival is anchorage-dependent, however Orford et al demonstrate that 
overexpression of β-catenin resulted in 75% of transfected MDCK cells to maintain 
viability in suspension for at least 16 hours, avoiding cell death by anoikis214,215. These 
findings support a potential mechanism whereby exogenous β-catenin uptake could induce 
an epithelial-to-mesenchymal transition that promotes anchorage-independent survival of 
single cells.  
 
Likewise, when considering the role of ADAM10 in promoting anchorage-independence, 
several studies have reported the ADAM family of proteases to cleave the extracellular 
domains of transmembrane proteins. In particular, ADAM10 specifically cleaves CD44 at 
the ectodomain in order to direct cell migration152. As a cell adhesion molecule, CD44 
expression plays an important role in cell-cell and cell-ECM interactions216. Perhaps the 
initial induction of a non-adherent breast cancer cell subpopulation and the inability of 
these cells to form mammospheres after exposure to lung-CM could be attributed, at least 
in part, to the loss of cell surface CD44 expression via ADAM10 cleavage. In a recent 
study performed by Mullooly et al, inhibition of ADAM10 with small interfering RNA 
(siRNA) resulted in significantly decreased invasion and migration of MDA-MB-231 
human breast cancer cells in vitro217. Moreover, using 117 primary tumour extracts they 
demonstrated that elevated ADAM10 protein expression correlates with high-grade, 
aggressive breast tumours217. Their results suggest that in the absence of ADAM10, CD44 
mediated cell-cell and cell-ECM interactions remain intact, resulting in a decrease in 
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migratory and invasive capacity of human breast cancer cells. In addition, a mechanistic 
model of cell motility proposed by Nagano et al highlights the importance of ADAM10 
after its activation by stretch-activated calcium ion (Ca2+) channels that promptly result in 
the cleavage of CD44 at the trailing end of the cell172. Taken together, both β-catenin and 
ADAM10 have previously been shown to promote cellular detachment and anchorage-
independent growth. As both proteins are soluble, can exist in the extracellular space, and 
are present within our lung-CM model, potentially one or both proteins may be involved 
in the induction of the observed non-adherent breast cancer subpopulation. 
 Potential Influence of Intracellular Proteins 
Lastly, considering that potential mechanisms exist allowing intracellular proteins to be 
packaged and exported from the cell in the form of exosomal vesicles, it is important to 
consider what implications this may pose for proteins that are exclusive to the intracellular 
space. Among the intracellular proteins that made up 86.6% of the proteins detected in the 
lung-CM, six proteins overlap with key regulators of the ALDH/RA signaling pathway. 
These proteins include: RBP1, ADH1, ALDH1A1, ALDH1A7, CRABP2, and FABP5. As 
previously discussed, it is not uncommon for cells to internalize and utilize proteins from 
the extracellular microenvironment. By expressing an endogenous ligand that mimics 
endocytic criteria for the receptor of interest, small molecules and proteins can be 
internalized into the cell218. In a groundbreaking discovery led by Sansone and colleagues, 
the horizontal transfer of the entire mitochondrial genome was packaged and transported 
to neighboring cells via extracellular vesicles219. Further, they determined that primary 
breast cancer samples from patients receiving hormonal therapy were deficient in oxidative 
phosphorylation, and that murine-derived mitochondrial DNA (mtDNA) packaged into 
extracellular vesicles successfully restored metabolic function in these cancer cells, 
inducing their exit from a dormant state219. Moreover, they demonstrated that this 
phenomenon also exists in stem-like cancer cells, as mutated mtDNA transfer from 
hormone therapy resistant cells into hormone therapy sensitive cells resulted in elevated 
self-renewal capacity219. Whether this mechanism of internalization is feasible with respect 
to ALDH/RA components in our model system, and if so, would render functional proteins 
has yet to be investigated. 
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Overall, the lung microenvironment is an abundant source of exogenous proteins that 
influence human breast cancer cell function. In the current study, we have identified several 
intra- and extracellular soluble proteins within lung-CM such as OPN, POSTN, β-catenin, 
and ADAM10 that may have specific roles in propagating cell migration, detachment from 
a monolayer, anchorage-independent growth, and differentiation. Interestingly, some of 
these exogenous proteins have been implicated in reducing stem-like phenotype and 
behaviour in experimental models, findings that are in keeping with our results. In addition, 
we have highlighted potential internalization mechanisms that could potentiate the 
packaging of intracellular machinery into extracellular vesicles for successful delivery into 
a recipient cell. 
 Lung-CM increases gene expression related to 
migration and decreases expression of CSC markers 
The stochastic model of cancer development speculates that the accumulation of random 
pro-oncogenic mutations within a cell is the source for aberrant growth patterns and 
subsequent formation of homogenous tumours220. Consequently, the approach to cancer 
therapy has remained relatively archaic, utilizing cytotoxic agents as a means for targeting 
a group of homogenous, highly proliferative cells, without discriminating between healthy 
and malignant cells221. Systemic chemotherapy is highly efficient at inducing apoptosis in 
cells that are actively undergoing mitosis, but ineffective at targeting quiescent cells that 
are arrested in G0-G1 phase of the cell cycle
221. Despite the phenotypic heterogeneity of 
tumour cells documented since the earliest days of cancer cell biology, the concept of intra-
tumour heterogeneity has gained very little traction until recently222,223. Mounting evidence 
suggests that a bulk tumour is far from homogenous, and instead, is composed of a myriad 
of distinct cell types that coordinate with each other to maintain tumour homeostasis and 
drive tumour development224. The emerging hierarchical CSC hypothesis has received a 
lot of attention as it challenges the stochastic model and provides a viable explanation for 
intra-tumour heterogeneity. The first studies to support the CSC model of cancer 
development in solid tumours was performed by Al-Hajj and colleagues when they 
successfully isolated a population of stem-like CD44+CD24- breast cancer cells that could 
recapitulate a breast tumour in 8 of 9 mice tested62. As few as 100 stem-like CD44+CD24- 
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breast cancer cells could reconstitute a tumour, while significantly higher numbers of non-
stem-like breast cancer cells were incapable of tumour formation62. Since its introduction, 
several studies have reported an association with the hematopoietic stem cell marker, 
ALDH, and its relation to the CSC model. In particular, ALDH activity in tumour cells has 
been demonstrated experimentally both in vitro and in vivo to increase invasive potential, 
migratory capacity, chemoprotection, and self-renewal in various types of solid 
tumours61,70,76,171,225,226. 
Clinically, breast cancer dissemination has been well documented to metastasize in an 
organ-specific pattern, often targeting the lung, BM, liver, brain and lymph nodes. Chu et 
al brought to light the importance of the soluble organ microenvironment, as they 
demonstrated that lung and BM microenvironments were especially capable of promoting 
migration of stem-like ALDHHiCD44+ breast cancer cell phenotype in vitro52. Research by 
Croker et al lent support to these findings as they reported increased incidence of 
spontaneous lung metastases by stem-like ALDHHiCD44+ breast cancer cells in vivo70. 
Together, work conducted by Chu et al and Croker et al suggest that the lung 
microenvironment supports the metastasis of stem-like ALDHhiCD44+ human breast 
cancer cells. The work presented in this thesis aimed to further build on these findings by 
investigating the potential role of the lung microenvironment in promoting a stem-like 
phenotype once the breast cancer cells reach the secondary site of metastasis. In doing so, 
we discovered that lung-CM not only decreased the proportion of cells expressing the stem-
like ALDHhiCD44+ phenotype, but also reduced the expression of several other genes 
related to stemness. Utilizing a discovery based approach, arrays composed of human 
cancer stem cells genes highlighted the effect lung-CM treatment has on human breast 
cancer cells. Collectively, we identified five genes that were affected by lung-CM 
treatment in both adherent and non-adherent cell subpopulation. Notably, genes related to 
a stem-like phenotype in breast cancer cells, CD24 and MUC1, were significantly 
downregulated in response to lung-CM. As a heavily glycosylated adhesion molecule, 
CD24 has been implicated in progression and metastatic spread of several cancers. In a 
meta-analysis conducted by Lee et al, CD24 expression was more frequently and highly 
expressed in malignant tumours of the breast and ovaries, relative to their benign 
counterparts227. Moreover, elevated levels of CD24 expression have been associated with 
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tumour progression and metastasis when investigating its role as a molecular marker of 
CSCs143. Although it remains a controversial subject, some studies have reported a 
decrease in CD24 protein expression in stem-like progenitor cells relative to differentiated 
cells143. We also observed a decrease in MUC1 gene expression following exposure to 
lung-CM. With its role in the expansion of pluripotent human embryonic stem cells, MUC1 
has been shown to be overexpressed in both ER+ and ER- breast cancers, in addition to its 
association with breast cancer cell side populations identified via exclusion of Hoechst 
33342 stain144. Together with a decrease in stem-like ALDHhiCD44+ breast cancer cell 
phenotype and impaired mammosphere formation, the decrease in CD24 and MUC1 gene 
expression in response to the lung microenvironment supports the idea that stemness is 
being lost in these human breast cancer cells.  
Despite observations that support diminished stem-like phenotype and behaviour, 
treatment with lung-CM affected the expression of several other genes related to increased 
aggressiveness. For example, both ATM and WEE1 were significantly downregulated in 
response to lung-CM. These genes represent a class of tumour signaling molecules 
involved in cell cycle control and have been implicated numerous times to have a role in 
cancer development. ATM is a serine/threonine kinase that has a central role in recognition 
of DNA damage, and responds accordingly by repairing double-stranded DNA breaks. 
Interestingly, in a study investigating 385 patients with gastric cancer, Han et al report a 
downregulation of ATM mRNA expression within tumour samples, relative to adjacent 
healthy tissue150. In addition, Kaplan-Meier analysis demonstrated patients with ATM-
negative tumours had a drastically lower survival rate compared to ATM-positive 
tumours150.  Similarly, increased ATM gene expression in breast carcinomas has been 
associated with a favorable patient outcome and prognosis151. WEE1 is also a 
serine/threonine kinase that is involved in regulating G2-M cell cycle checkpoint. The main 
role of WEE1 is to arrest mitotic entry in response to DNA damage, and its impairment has 
led to the loss of DNA-damage induced apoptosis and aberrant mitosis, however its role in 
carcinogenesis remains controversial146. Studies that have successfully inhibited WEE1 
activity report an anticarcinogenic role in basal and TN breast cancer cells, while WEE1 
overexpression in both melanoma and vulvar squamous cell carcinoma have been 
associated with poor disease-free survival and malignancy228-231. Although there is not a 
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clear consensus on the role of WEE1 in tumour development, it is likely that a decrease in 
gene expression of ATM and/or WEE1 may contribute to heightened malignancy due to 
loss of cell cycle control, despite the decrease in stemness.  
Of the five genes of interest that were consistently affected by lung-CM treatment in both 
adherent and non-adherent breast cancer subpopulations, the only gene that exhibited an 
increase in expression was metastasis/migration related CXCL8, a precursor to interleukin 
8 (IL8). Originally identified as a monocyte-derived factor, IL8 has been reported to recruit 
and activate neutrophils to site of inflammation, as well as the propagation of epithelial-to-
mesenchymal transition in human cancer cells147,148. In breast cancer, IL8 expression is 
significantly increased in more aggressive ER- subtypes and has been reported to promote 
metastasis through increased cell invasion and angiogenesis148,232. Again, this data suggests 
that although lung-CM diminishes stem-like phenotype and behavior, it may still support 
metastatic capacity through mechanisms such as increased motility and cell recruitment. 
Many studies have documented the importance of ALDH activity in combination with cell 
surface markers, such as CD44, to isolate populations of cancer cells that behave in an 
aggressive manner both in vitro and in vivo. The unexpected findings of this thesis do not 
discredit the tumourigenic potential of stem-like cell populations, but instead suggest that 
stem-like characteristics are not compulsory for tumour development once in the secondary 
lung microenvironment. Our gene array analysis demonstrates that CSC-related genes were 
downregulated, along with the downregulation of tumour signaling molecules involved in 
cell cycle regulation. Moreover, the upregulation of CXCL8 suggests the soluble lung 
microenvironment may promote cell migration. Taken together, although stemness of 
breast cancer cells is decreased after exposure to lung-CM, these cells may still retain 
metastatic capacity in order to drive disease progression in a CSC-independent manner. 
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 Possible Limitations of the Study 
The model system used in this thesis is based on an ex vivo representation of the soluble 
organ microenvironment, and with this, is an imperfect model that relies on several 
assumptions.  
The first assumption is that breast cancer metastasis is primarily influenced by the soluble 
organ microenvironment. Several studies have recently addressed the importance of the 
insoluble organ microenvironment in providing the necessary infrastructure for tumour 
development, with parameters such as scaffold composition, density, pore size, and elastic 
modulus affecting in vitro tumour development233,234. Thus, to more accurately depict the 
role of the entire organ microenvironment regarding preferential metastasis and stemness 
in vitro, it would be necessary to incorporate both soluble and insoluble components. 
The second assumption is that the composition of the lung-CM media will truly reflect the 
soluble lung microenvironment. During the process of generating lung-CM, murine lungs 
are mechanically dissociated to allow soluble proteins to be secreted into the culture 
medium. Although the proteins that make their way into the conditioned media are specific 
to the lung tissue, they are not necessarily all natively secreted proteins and many would 
generally remain confined within the cell of origin in vivo. During the dissociation process, 
cells of the lung are forcibly lysed and their contents released into the culture medium, 
resulting in a lung-CM that is enriched in both intracellular and extracellular related 
proteins. We observed that 86.6% of proteins within the lung-CM belong to the 
intracellular compartment. This is not an issue with BM-CM as its generation requires 
several passages that likely discard any intracellular contents that may be present due to 
cell lysis. An improved method for generating lung-CM would be one that is less prone to 
cell lysis, such as using bead mill homogenizers235.  
The third assumption is that breast cancer cells and their associated stem-like 
characteristics will behave in a similar manner when exposed to lung-CM derived from 
either healthy or diseased lung tissue. As our study utilizes healthy murine tissue to 
generate lung and BM-CM, there is the potential that we are not presenting a fully accurate 
model for metastasis to secondary organs in a host that first developed a primary tumor. 
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The concept of metastatic priming has been recently introduced and supported by several 
studies; whereby the presence of a primary tumour may “prime” the microenvironment of 
a distant secondary organ prior to the arrival of metastatic cancer cells236-238. Permitting 
tumour development following orthotopic injection of human breast cancer cells into the 
mammary fat pad of mice could allow potential “priming” mechanism to influence the 
microenvironments of secondary sites of metastasis. 
The fourth assumption is with regards to our animal model and generation of organ-CM. 
Primarily, we utilized an immunocompromised murine model to generate our organ-CM 
treatments as future studies would utilize the inherent NOD/SCID mutation to improve 
rates of human tissue engraftment in vivo. Due to their reduced innate immunity (NOD 
mutation) and complete T- and B-cell deficiency (SCID mutation), these mutations may 
have noticeable effects on the lung tissue239. Within the lower respiratory tract, alveolar 
macrophages represent the largest population of leukocytes in healthy lung tissue capable 
of ingesting microbes, and, initiating an immune response by presenting cell surface 
antigens240.  Thus, it is likely these alveolar macrophages (among other immune cells) are 
significantly reduced in our model of the healthy lung and may be beneficial to utilize an 
immunocompetent model instead. Further, CO2 asphyxiation was carried out during 
euthanasia. This method helps to maintain our lung samples intact post-euthanasia, 
however may damage the microarchitecture within the lung tissue. It has been reported that 
rapid asphyxia with CO2 results in alveolar atrophy and hemorrhaging within murine lungs, 
thus compromising the native state of healthy lungs within our model241. An alternative 
approach could be euthanization by retroorbital ketamine-xylazine injections242. Although 
this method may appear distasteful, it is more humane than other IV injections and better 
conserves the integrity of lung tissue by avoiding asphyxiation242.  
The final assumption concerns the use of immortalized cell lines. Although cell lines are 
routinely used in the cancer research community, their behaviour and intrinsic mechanisms 
can become altered over successive passages and the foreign in vitro culture conditions. 
The breast cancer cell lines used in this study were once derived from individual primary 
patient samples, however their immortalization is linked to inherent mutations that allow 
for continuous growth outside of their native microenvironment. Preferably, a model 
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utilizing primary breast cancer cells would more accurately depict the underlying 
biological processes of cancer pertaining to phenotype and behaviour243. 
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 Future Directions 
 
While this thesis investigated several important questions pertaining to stem-like breast 
cancer phenotype and function in response to the lung and bone microenvironments, there 
are several avenues of investigation that need to be addressed in future studies to better 
understand the role of these organ microenvironments in metastasis.  
First, as lung-CM treatment decreased cell surface CD44 expression and induced a non-
adherent breast cancer subpopulation incapable of mammosphere formation, it is important 
to investigate whether these cells have lost adhesive properties through CD44-mediated 
interactions. A potential resolution could be to coat tissue culture plastic with a known 
CD44 receptor ligand, such as OPN, and monitor whether non-adherent breast cancer cells 
retain their capacity to re-adhere when provided suitable conditions. If the breast cancer 
cells remain non-adherent after exposure to a known ligand, one can infer that loss of cell 
surface CD44 may not be responsible for the non-adherent phenotype. 
Second, as we only investigated the composition of the lung-CM, it is necessary to perform 
similar analysis on the BM-CM. Understanding which factors are present within the BM-
CM would provide insight into the effects that BM-CM imposed on our adherent and non-
adherent breast cancer cell subpopulations. Furthermore, by assessing the composition of 
BM-CM, we would be able to effectively compare which proteins are similar or different 
between the lung-CM and BM-CM models. 
Third, considering the BM is a rich stem cell niche for hematopoietic stem cells, it would 
be interesting to investigate whether CSC-related genes are affected in breast cancer cells 
after treatment with BM-CM. Using a similar human cancer stem cell gene array used for 
lung-CM analysis, some insight would be provided with regards to changes in CSC gene 
expression and whether similar genes were affected by both lung-CM and BM-CM. 
Finally, future studies must move these findings into an in vivo model. Recapitulating the 
native organ microenvironment in vitro is a significant feat, and often, those who attempt 
its representation experience shortcomings. Although many studies highlight the 
tumourigenic and metastatic potential of stem-like cancer cells, our study indicates that the 
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stem-like phenotype may be diminished once breast cancer cells are exposed to the lung 
microenvironment. However, the induction of a viable, non-adherent population of breast 
cancer cells with gene expression patterns suggestive of increased migratory and/or 
metastatic capacity warrants further investigation of the true functional effect of these cells 
in vivo, independent of the CSC context. 
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 Final Conclusions 
The purpose of this thesis was to test the hypothesis that the lung and/or bone 
microenvironments could promote stem-like phenotype and function in human breast 
cancer cells. As metastasis is the leading cause of cancer-related deaths, it is of utmost 
importance to strengthen our understanding of tumour dissemination and development at 
distant secondary sites. Prior to this study, our lab has focused on the “getting there” 
perspective of metastasis and have demonstrated that the lung microenvironment can 
promote chemotactic migration in both whole cell populations and sorted ALDHhiCD44+ 
stem-like human breast cancer cell populations. Here, we have begun investigation into the 
“establishment” stage of tumour metastasis. In particular, this thesis has directed attention 
to breast cancer cell stemness and plasticity, investigating whether the secondary 
microenvironment can mediate stem-like attributes associated with the CSC theory of 
cancer development.  
 
Taken together, our findings (summarized in Table 6) did not support the hypothesis of 
this thesis. Treatment with lung-CM decreased stem-like characteristics, namely ALDH 
and CD44 phenotype. Further, these cells were not capable of producing mammospheres, 
which is also a common in vitro measure of stemness. Despite these findings, evidence in 
the literature also supports the notion that cancer cells with decreased ALDH activity and 
CD44 expression can be more tumourigenic and correlate with advanced stage cancers. 
Further, our data suggests that the migration related gene, CXCL8, is upregulated after 
lung-CM treatment, while CSC markers (CD24 and MUC1) and tumour signaling 
molecules (ATM and WEE1) are downregulated. Previous studies in our lab provide 
evidence that lung-CM supports existing ALDHhiCD44+ cells, with respect to migration 
and growth, however the findings of this thesis indicates that neither lung-CM or bone-CM 
actually promote stemness of breast cancer cells. Nonetheless, we did uncover an intriguing 
non-adherent, viable subpopulation of breast cancer cells that are induced by lung-CM, and 
this population will be important to investigate further in the future to determine if and how 
the lung microenvironment may promote survival and migration of breast cancer cells 
using mechanisms distinct from CSC pathways.  
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8 APPENDICES 
Appendix 1. Approved animal use protocol 
 
 
 
AUP Number: 2009-064  
PI Name: Allan, Alison   
AUP Title: Role of ALDH+/CD44+ stem-like cells in breast cancer progression and treatment  
Approval Date:  10/27/2017  
 
Official Notice of Animal Care Committee (ACC) Approval:  
Your new Animal Use Protocol (AUP)  2009-064:9:  entitled " Role of ALDH+/CD44+ stem-like cells in breast cancer progression and treatment" 
has been APPROVED by the Animal Care Committee of the University Council on Animal Care. This approval, although valid for up to four years, 
is subject to annual Protocol Renewal. 
 
Prior to commencing animal work, please review your AUP with your research team to ensure full understanding by everyone listed within this 
AUP. 
 
As per your declaration within this approved AUP, you are obligated to ensure that: 
1) Animals used in this research project will be cared for in alignment with: 
a) Western's Senate MAPPs 7.12, 7.10, and 7.15 
http://www.uwo.ca/univsec/policies_procedures/research.html  
b) University Council on Animal Care Policies and related Animal Care Committee procedures 
http://uwo.ca/research/services/animalethics/animal_care_and_use_policies.htm  
  
2) As per UCAC's Animal Use Protocols Policy, 
a) this AUP accurately represents intended animal use; 
b) external approvals associated with this AUP, including permits and scientific/  departmental peer approvals, are complete and accurate; 
c) any divergence from this AUP will not be undertaken until the related Protocol Modification is approved by the ACC; and 
d) AUP form submissions - Annual Protocol Renewals and Full AUP Renewals - will be submitted and attended to within timeframes outlined by 
the ACC. 
e) http://uwo.ca/research/services/animalethics/animal_use_protocols.html  
    
3) As per MAPP 7.10 all individuals listed within this AUP as having any hands-on animal contact will 
a) be made familiar with and have direct access to this AUP; 
b) complete all required CCAC mandatory training (training@uwo.ca); and 
c) be overseen by me to ensure appropriate care and use of animals. 
 
4) As per MAPP 7.15, 
a) Practice will align with approved AUP elements; 
b) Unrestricted access to all animal areas will be given to ACVS Veterinarians and ACC Leaders; 
c) UCAC policies and related ACC procedures will be followed, including but not limited to: 
 i) Research Animal Procurement 
 ii) Animal Care and Use Records 
 iii) Sick Animal Response 
 iv) Continuing Care Visits 
5) As per institutional OH&S policies, all individuals listed within this AUP who will be using or potentially exposed to hazardous materials will 
have completed in advance the appropriate institutional OH&S training, facility-level training, and reviewed related (M)SDS Sheets, 
http://www.uwo.ca/hr/learning/required/index.html  
  
Submitted by: Copeman, Laura 
on behalf of the Animal Care Committee 
University Council on Animal Care 
  
 
Dr.Timothy Regnault, 
Animal Care Committee Chair 
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Appendix 2. Exposure to organ-CM did not affect protein expression of ALDH1A3 in 
human breast cancer cells. MDA-MB-468 human breast cancer cells were exposed to 
lung-CM, BM-CM, and basal control for 72 hours. Both adherent and non-adherent 
subpopulations were harvested and cell lysates utilized for analysis of ALDH1A3 protein 
expression by western blot. (A) Treatment with either lung-CM or BM-CM did not affect 
ALDH1A3 protein expression relative to basal media. All data are normalized to the basal 
control group and β-Actin. (B) Representative cropped image of western blot probing for 
ALDH1A3 (56 KDa) and β-Actin (42 KDa). Lanes are labelled based on treatment 
condition received (lung, bone, or basal) and associated with either adherent (A) or non-
adherent (N-A) subpopulations. Experiments were performed a minimum of 3 times and 
analyses were performed using 2-way ANOVA and Dunnett’s post hoc test. Data is 
presented as mean ± SEM. All significant values (*) are relative to the respective treatments 
adherent population (p<0.05). 
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Appendix 3. Relative mRNA expression levels of cell lines and cell subpopulations in 
response to basal media. MDA-MB-468 (Adherent and Non-adherent subpopulations) 
and SUM159 cells were exposed to basal media for 24 hours in culture (37°C, 5% CO2) 
without media replacement. Cells were harvested and RNA was analyzed by RT-qPCR to 
assess expression of CD44, ALDH1A1 and ALDH1A3. All analyses were normalized to 
GAPDH expression and shown as relative expression levels. Experiments were performed 
a minimum of three times and statistical analyses were performed using one-way ANOVA 
and Dunnett’s post hoc test. Data is presented as mean ± SEM. All significant values (*) 
are relative to the SUM159 cell line with each gene respectively (p<0.05, N=3).  
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Appendix 4. Average Ct values of MDA-MB-468 cells following qRT-PCR Human 
Cancer Stem Cell gene array analysis. Adherent (A) and Non-adherent (NA) cell 
subpopulations were analyzed and data sets are colour-coded based on subpopulations 
being compared: Basal-A vs Basal-NA (Black), Lung-A vs Lung-NA (Blue), Basal-NA vs 
Lung-NA (Orange), and Basal-A vs Lung-A (Green). Raw data acquired using Qiagen’s 
Data Analysis Center® software. 
Gene 
Name 
Average Ct Values 
Basal – A 
(Control) 
Basal – NA 
(Sample) 
Lung – A 
(Control) 
Lung – NA 
(Sample) 
Basal – NA 
(Control) 
Lung – NA 
(Sample) 
Basal – A 
(Control) 
Lung – A 
(Sample) 
ABCB5 40 40 40 40 40 40 40 40 
ABCG2 40 40 39.53 39.68 40 39.68 40 39.53 
ALCAM 25.56 26.39 26.29 28.04 26.39 28.04 25.56 26.29 
ALDH1A1 25.12 25.75 25.74 27.5 25.75 27.5 25.12 25.74 
ATM 30.93 30.9 32.76 33.78 30.9 33.78 30.93 32.76 
ATXN1 27.01 27.78 28.4 30.12 27.78 30.12 27.01 28.4 
AXL 35.02 32.52 31.51 32.87 32.52 32.87 35.02 31.51 
BMI1 27.22 27.58 27.41 28.92 27.58 28.92 27.22 27.41 
BMP7 30.92 31.59 30.29 31.85 31.59 31.85 30.92 30.29 
CD24 25.96 27.03 28.53 29.32 27.03 29.32 25.96 28.53 
CD34 40 38.81 40 39.84 38.81 39.84 40 40 
CD38 35.99 34.74 35.95 37.12 34.74 37.12 35.99 35.95 
CD44 22.59 23.05 22.22 23.5 23.05 23.5 22.59 22.22 
CHEK1 26.6 28.08 27.15 29.19 28.08 29.19 26.6 27.15 
DACH1 34.13 35.52 36.2 38.86 35.52 38.86 34.13 36.2 
DDR1 26.66 27.16 26.46 28.2 27.16 28.2 26.66 26.46 
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DKK1 28.29 29.47 30.32 30.83 29.47 30.83 28.29 30.32 
DLL1 40 37.79 38.62 39.15 37.79 39.15 40 38.62 
DLL4 40 38.61 40 38.33 38.61 38.33 40 40 
DNMT1 25.46 26.11 25.5 27.31 26.11 27.31 25.46 25.5 
EGF 31.25 30.82 30.68 32.72 30.82 32.72 31.25 30.68 
ENG 30.4 30.53 29.88 31.29 30.53 31.29 30.4 29.88 
EPCAM 23.48 24.17 23.64 25.16 24.17 25.16 23.48 23.64 
ERBB2 29.76 30.28 29.76 31.76 30.28 31.76 29.76 29.76 
ETFA 23.78 24.83 24.75 26.29 24.83 26.29 23.78 24.75 
FGFR2 29.32 29.98 29.35 31.33 29.98 31.33 29.32 29.35 
FLOT2 26.37 26.75 26.28 27.95 26.75 27.95 26.37 26.28 
FOXA2 40 40 39.43 39.67 40 39.67 40 39.43 
FOXP1 28.96 29.32 29.41 30.82 29.32 30.82 28.96 29.41 
FZD7 30.01 30 30.17 31.3 30 31.3 30.01 30.17 
GATA3 29.5 30.17 29.76 31.51 30.17 31.51 29.5 29.76 
GSK3B 26.29 26.65 26.62 28.26 26.65 28.26 26.29 26.62 
HDAC1 25.15 25.53 25.57 27.25 25.53 27.25 25.15 25.57 
ID1 27.27 28.25 25.79 27.88 28.25 27.88 27.27 25.79 
IKBKB 29.59 29.54 29.29 30.59 29.54 30.59 29.59 29.29 
CXCL8 32.66 29.2 29.17 28.09 29.2 28.09 32.66 29.17 
ITGA2 29.89 30.04 28.81 30.13 30.04 30.13 29.89 28.81 
ITGA4 38.52 40 40 40 40 40 38.52 40 
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ITGA6 27.36 27.75 26.44 28.72 27.75 28.72 27.36 26.44 
ITGB1 26.49 27.04 26.3 28.37 27.04 28.37 26.49 26.3 
JAG1 27.88 28.1 26.14 27.7 28.1 27.7 27.88 26.14 
JAK2 31.17 31.56 31.22 33.46 31.56 33.46 31.17 31.22 
KIT 33.24 35.12 38.82 38.85 35.12 38.85 33.24 38.82 
KITLG 27.15 28.01 28.18 30.64 28.01 30.64 27.15 28.18 
KLF17 37.08 34.83 35.36 36.83 34.83 36.83 37.08 35.36 
KLF4 29.35 29.58 28.56 30.38 29.58 30.38 29.35 28.56 
LATS1 28.38 28.78 28.65 30.5 28.78 30.5 28.38 28.65 
LIN28A 34.14 33.21 35.45 36.18 33.21 36.18 34.14 35.45 
LIN28B 38.76 40 40 39.16 40 39.16 38.76 40 
MAML1 30.47 30.73 30.6 32.32 30.73 32.32 30.47 30.6 
MERTK 34.74 33.79 33.44 35.48 33.79 35.48 34.74 33.44 
MS4A1 40 40 40 40 40 40 40 40 
MUC1 26.52 26.97 28.37 30.15 26.97 30.15 26.52 28.37 
MYC 24.12 25.47 24.21 26.25 25.47 26.25 24.12 24.21 
MYCN 31.68 33.42 33.29 36.35 33.42 36.35 31.68 33.29 
NANOG 38.63 35.79 40 38.63 35.79 38.63 38.63 40 
NFKB1 29.32 29.66 29.01 31.23 29.66 31.23 29.32 29.01 
NOS2 38.34 35.4 36.73 39.26 35.4 39.26 38.34 36.73 
NOTCH1 31.55 32.05 31.28 32.86 32.05 32.86 31.55 31.28 
NOTCH2 27.18 27.81 28.14 30.15 27.81 30.15 27.18 28.14 
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PECAM1 36.08 35.63 36.83 38.08 35.63 38.08 36.08 36.83 
PLAT 39.97 38.59 37.39 38.77 38.59 38.77 39.97 37.39 
PLAUR 27.63 27.68 26.39 27.59 27.68 27.59 27.63 26.39 
POU5F1 33.03 31.71 32.77 33.68 31.71 33.68 33.03 32.77 
PROM1 25.86 26.44 27.03 28.54 26.44 28.54 25.86 27.03 
PTCH1 33.8 35.36 34.17 37.1 35.36 37.1 33.8 34.17 
PTPRC 38.74 40 40 39.32 40 39.32 38.74 40 
SAV1 25.76 26.89 25.94 28.07 26.89 28.07 25.76 25.94 
SIRT1 27.41 27.89 27.73 29.51 27.89 29.51 27.41 27.73 
SMO 32.91 33.59 34.17 35.33 33.59 35.33 32.91 34.17 
SNAI1 37.26 35.13 38.13 37.16 35.13 37.16 37.26 38.13 
SOX2 40 40 40 40 40 40 40 40 
STAT3 24.81 25.44 25.1 26.86 25.44 26.86 24.81 25.1 
TAZ 27.96 27.92 27.29 29.02 27.92 29.02 27.96 27.29 
TGFBR1 27.09 27.34 26.84 28.71 27.34 28.71 27.09 26.84 
THY1 35.94 37.51 37.71 38.32 37.51 38.32 35.94 37.71 
TWIST1 38.82 40 39.02 40 40 40 38.82 39.02 
TWIST2 30.16 30.83 29.63 31.47 30.83 31.47 30.16 29.63 
WEE1 26.15 27.06 27.7 29.88 27.06 29.88 26.15 27.7 
WNT1 40 39.42 40 40 39.42 40 40 40 
WWC1 26.62 27.05 26.55 28.57 27.05 28.57 26.62 26.55 
YAP1 25.26 25.75 25.29 27.24 25.75 27.24 25.26 25.29 
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ZEB1 39.04 37.05 36.51 38.43 37.05 38.43 39.04 36.51 
ZEB2 40 40 40 40 40 40 40 40 
ACTB 19.57 20.46 19.95 21.43 20.46 21.43 19.57 19.95 
B2M 23.37 24.49 24.66 26.14 24.49 26.14 23.37 24.66 
GAPDH 21.11 22.05 21.52 22.65 22.05 22.65 21.11 21.52 
HPRT1 26.48 27.41 27.43 29.04 27.41 29.04 26.48 27.43 
RPLP0 19.55 20.21 20.19 21.47 20.21 21.47 19.55 20.19 
HGDC 38.61 40 40 40 40 40 38.61 40 
RTC 21.91 22.15 22.42 22.23 22.15 22.23 21.91 22.42 
RTC 22.02 22.19 22.52 22.27 22.19 22.27 22.02 22.52 
RTC 21.97 22.17 22.42 22.15 22.17 22.15 21.97 22.42 
PPC 19.87 19.92 20.05 20.01 19.92 20.01 19.87 20.05 
PPC 19.57 19.78 20 19.86 19.78 19.86 19.57 20 
PPC 19.88 20.08 20.01 19.99 20.08 19.99 19.88 20.01 
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